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1 INTRODUCTION  
Malignant melanoma is a very aggressive form of skin cancer that often is refractory 
to standard treatments such as chemo- and radiotherapy. To this day, surgical 
resection of the primary tumor at an early stage is the only curative treatment for this 
disease. Therapeutic strategies aiming to activate the patient´s immune system to 
eliminate malignant cells may provide the basis for a more effective melanoma 
treatment.1  
Immunoadjuvant therapy with Interferon-α (IFN-α) and topical treatment with the 
synthetic TLR 7/8 ligand Imiquimod (IMQ) have been shown to be clinically effective 
in melanoma patients.2-5 Direct anti-tumor activity as well as stimulation of the 
immune system are thought to contribute to the efficacy of both agents.6-11 The 
induction of the cytotoxic molecule tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL), particularly on plasmacytoid dendritic cells (pDCs), might play an 
important role in IFN-α and IMQ-mediated melanoma containment.12-14 Both in man 
and mice, the regression of cutaneous tumors upon topical IMQ-treatment was 
associated with an infiltrate of pDCs expressing TRAIL.12, 13 Since IMQ-induced 
TRAIL expression was shown to be dependent on IFN-α in vitro, TRAIL+ pDCs could 
also play a role in melanoma patients treated with IFN-α.14  
 
In this diploma thesis, the role of TRAIL in immuno-adjuvant therapy of melanoma 
with IFN-α or IMQ was studied in vitro with a focus on TRAIL-mediated cytotoxic 
effector functions of pDCs.  
We were particularly interested in: 
1) Direct apoptotic and antiproliferative effects of IFN-α on melanoma cells. 
2) Susceptibility of different melanoma cell lines to TRAIL and the correlation of 
TRAIL-sensitivity with TRAIL receptor (TRAIL R) expression. 
3) Whether IMQ- and IFNA-activated pDCs acquire TRAIL-dependent cytotoxic 
effector functions in vitro. 
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In chapter 2 of this diploma thesis the literature relevant to this study is reviewed. It 
contains information on i) malignant melanoma and current therapeutic options, ii) 
the function of IFN-α and IMQ and their role in the treatment of malignant melanoma, 
iii) the cytotoxic molecule TRAIL and iv) dendritic cell biology with a focus on pDCs. 
Chapter 3 provides a detailed description of the materials and methods used in this 
study. We first characterized established human melanoma cell lines and such 
generated from stage IV melanoma patients with respect to their TRAIL and TRAIL R 
expression using flow cytometry and real-time PCR. The antiproliferative properties 
of IFN-α on melanoma cells were assessed using 3H-Thymidine incorporation and 
the apoptotic effects of TRAIL and IFN-α were studied using Annexin V/PI staining. 
The effect of IMQ or IFN-α-pretreatment on TRAIL-induced apoptosis in melanoma 
cells was also investigated. Finally, the cytotoxic potential of IFN-α and IMQ-
activated, TRAIL+ pDCs against melanoma targets were assessed. The results from 
our research are presented in chapter 4 and conclusions are drawn in chapter 5. 
 
Our findings implicate that, in addition to other immunostimulatory effects, the 
induction of TRAIL on immune cells could play a role in IFN-α and IMQ-mediated 
melanoma containment. Particularly pDCs may acquire important TRAIL-dependent 
cytotoxic functions in both therapeutic settings. 
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2 BACKGROUND 
2.1 Malignant melanoma 
Malignant melanoma is a neoplasm of melanocytes, the cells responsible for skin 
pigmentation. Although melanoma accounts for only 4% of skin cancer incidences, it 
is responsible for over 70% of deaths from skin cancer.15 The incidence of melanoma 
in developed countries is approximately 9 per 100,000 in men and women. Since the 
1980s this number has increased dramatically but mortality has not (Figure 1).16 This 
is most probably due to earlier detection and surgical resection of the primary tumor 
rather than improved therapeutic options.  
This chapter will provide an overview of melanoma development from benign 
melanocytes to metastatic melanoma and clinical melanoma staging. Further, 
therapeutic strategies against this disease will be discussed. 
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Figure 1: Melanoma incidence and mortality in Austria 1983-2008.16 
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2.1.1 Melanocytes 
Melanocytes reside on the basement membrane of the epidermis but are also found 
in other organs like the eye, ear, leptomeninges, bones and heart.17 Their main 
function is the production of the pigment melanin and its delivery to nearby 
keratinocytes where it absorbs UV radiation to shield the cellular DNA from UV-
induced damage.18 Skin tanning is a consequence of this mechanism, as melanin 
synthesis is particularly enhanced in response to UV exposure.  
In contrast to keratinocytes, the predominant cell type in the epidermis, melanocytes 
are low in numbers (one melanocyte per 30-40 keratinocytes),19 long-lived, and have 
a low proliferation potential.18 To ensure melanocyte survival, they are endowed with 
antiapoptotic mechanisms such as the constitutive expression of the antiapoptotic 
protein Bcl-2.20 Due to their longevity and their relative resistance to apoptosis 
melanocytes are prone to accumulate mutations over the years, potentially 
culminating in their malignant transformation to melanoma.18 
 
 
 
 
Figure 2: A melanocyte in its epidermal environment. The melanocyte is localized in the basal cell 
layer of the epidermis. Melanin-containing vesicles (melanosomes) are formed in the golgi apparatus 
and transported to keratinocytes via dendritic protrusions. 
 
 
BACKGROUND - Malignant melanoma 
 5 
2.1.2 Incidence and risk factors 
The greatest external risk factor for melanoma development is UV exposure. 
Melanoma incidence is higher in countries with high UV exposure. It is also 
associated with UV-sensitive skin types and the occurrence of severe sunburns, 
particularly during infancy and puberty. Whereas the risk of developing melanoma at 
UV-unexposed regions of the body (palms, soles, mucosa) is rare and similar in all 
ethnicities, caucasians bear a much higher predisposition toward the development of 
melanoma at other sites of the body. 21 
For the development of melanoma, a series of genetic lesions are required which 
usually take years to accumulate. Therefore, the incidence in children and young 
adults is rather low and it increases with age. In some families, there is an increased 
occurrence of melanoma. Members of these families often carry mutations in genes 
that regulate the cell cycle. A defect in CDKN2A, a gene that is involved in cell cycle 
control, is found in 25-40% of melanoma-prone families.22 
Another risk factor for melanoma are multiple and atypic nevi. For patients with a 
history of melanoma the chance of developing a second primary tumor is greatly 
elevated (about 3% of patients develop a second melanoma within 10 years of 
resection of the first tumor). 1 
Regular dermatologic screenings are the most effective measure against melanoma. 
Depending on the number of nevi and other risk factors, examinations every 3-12 
months are recommended. 
2.1.3 Oncogenic transformation: The Clark model of melanoma progression 
Melanoma is a polygenic disease that requires the progressive acquisition of multiple 
mutations in genes involved in cell cycle control, DNA repair and apoptosis (Figure 
3). These genetic lesions can be related to histologic and phenotypic changes that 
are described in the Clark model of melanoma progression.23 According to this 
model, the first event is the formation of a benign nevus. Neval melanocytes display 
abberant growth, often due to deregulation of the mitogen-activated protein kinase 
(MAPK) pathway (e.g. constant activation of BRAF in up to 82% of benign nevi).24 
Cell growth, although increased, is still limited in benign nevi, probably due to 
oncogene-induced senescence.25 Such lesions are found on the skin of every person 
and rarely progress to cancer.  
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The development of a dysplastic nevus, either arising from an existing benign nevus 
or at a new site on the skin is the next step toward oncogenic transformation. It is 
marked not only by aberrant cell growth but also by defects in DNA repair and 
apoptotic pathways. In dysplastic nevi, the cell cycle control gene CDKN2A and 
PTEN, a gene involved in growth control and regulation of apoptosis, are often 
disrupted.22 
During the next step, the radial growth phase, the cells proliferate mainly 
intraepidermally but a few cells can invade the papillary dermis.  
The transition from radial to vertical growth phase is characterized by alterations in 
the expression of cell adhesion molecules (integrins and cadherins) causing 
increased motility and reduced adhesion to epidermal fibroblasts. This gives the cells 
the ability to further colonize the dermis and form expansive tumor nodules.  
Integrins are a family of cell surface receptors that mediate cell attachment to the 
extracellular matrix (ECM) and transduce signals affecting proliferation and 
migration.26 Alterations in integrin expression can increase melanoma cell motility 
through reorganization of the cytoskeleton and stimulation of the expression of matrix 
metalloproteinase 2 (MMP2), which degrades collagen in the basement membrane.22 
Cadherins are a class of membrane proteins with an important role in cell adhesion. 
E-cadherin (epithelial) is expressed by epithelial cells like melanocytes and 
keratinocytes and mediates adhesion between these cell types. Downregulation of E-
cadherin and switch to N-cadherin (neural) expression endows melanoma cells with 
the ability to form contacts with dermal fibroblast and other mesenchymal cells, 
facilitating the establishment of metastases.27  
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Figure 3: Model of melanoma progression and associated genetic lesions. Figure taken from 
Miller et al., 200622 
 
The final step, metastasis formation, is marked by spread to and successful 
colonization of other sites of the skin, draining lymph nodes (LNs) and finally distant 
organs by melanoma cells. Early metastases usually spread through the lymphatic 
system and occur either close to the primary tumor (satellite metastases, ≤2 cm from 
primary tumor), in the skin between 2 cm from the primary tumor and the sentinel LN 
(in transit metastases) or in the sentinel LN (LN metastases). The formation of distant 
metastases is mainly caused by the spread of tumor cells through blood vessels. The 
three most common sites for distant melanoma metastases are, in descending order, 
lungs, liver and brain.28   
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2.1.4 Clinical aspects of melanoma 
In an effort to provide universal guidelines for the estimation of disease severity in 
cancer patients, the American Joint Committee on Cancer (AJCC) developed a 
Cancer Staging Manual, which is continually refined and updated since 1977.29 The 
manual is based on the tumor-node-metastasis (TNM) classification system using 
prognostic markers to categorize melanoma patients to four different stages of 
disease (Table 1, Table 2).30  
The T categories T1-4 are defined by the thickness of the tumor. The presence or 
absence of ulceration further divides the categories in subgroups (a: no ulceration, b: 
with ulceration). Melanoma ulceration is strongly connected with decreased patient 
survival. In fact, ulceration of the primary tumor is associated with survival rates 
similar to those of a patient with a non-ulcerated tumor of the next highest T category 
(Table 2).30 The number of metastases in the regional LNs and in transit (in lymphatic 
vessel) or satellite metastases is the main criterion for the N classification. The three 
main categories N1-3 are further divided into subgroups a-c by the size and type of 
the metastases. The M classification groups distant metastases according to their 
location and the associated survival rates.  
A staging system has been deduced from the TNM classification, grouping patients 
with localized melanoma and no evidence of metastasis to stage I and II, those with 
regional metastases to stage III and those with distant metastases to stage IV. 
According to the corresponding survival rates the stages are further divided into 
subgroups A-C (Table 2). Generally, there is a negative correlation between tumor 
stage and patient survival. Ulcerated primary tumors thicker than 4mm exhibit a 
particularly high risk for metastasis and, due to their aggressiveness, are associated 
with survival rates even poorer than those of stage III melanoma (Table 2). 
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Table 1: Melanoma TNM classification (adapted from Balch et al., 2001 and the AJCC cancer 
staging manual 7th edition)29-31 
 
T classification Thickness Ulceration status 
  T0 No evidence of primary tumor  
  Tx Primary tumor cannot be assessed (e.g.: curettaged, regressed)   
  T1 
 
≤ 1.0 mm 
 
a: w/o ulceration 
b: with ulceration 
  T2 
 
1.01-2.0 mm 
 
a: w/o ulceration 
b: with ulceration 
  T3 
 
2.01-4.0 mm 
 
a: w/o ulceration 
b: with ulceration 
  T4 
 
> 4.0 mm 
 
a: w/o ulceration 
b: with ulceration 
N classification No. of metastatic nodes Nodal metastatic mass 
  N0 No evidence of local metastasis  
  Nx Regional nodes cannot be 
assessed   
  N1 
 
1 node 
 
a: micrometastasis 
b: macrometastasis 
  N2 
 
  2-3 nodes 
 
a: micrometastasis 
b: macrometastasis 
c: in transit/satellite metastases w/o 
metastatic nodes 
  N3 
 
≥ 4 nodes or matted nodes or in transit/satellite metastases with metastatic 
nodes 
M classification Site Serum lactate dehydrogenase 
  M0 No evidence of distant metastasis Normal 
  M1a Distant skin, subcutaneous, nodal metastases Normal 
  M1b Lung metastases Normal 
  M1c 
 
Other visceral metastases 
Distant metastases 
Normal 
Elevated 
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Table 2: Melanoma TNM staging and 10-year survival rates (adapted from Balch et al., 2001)30 
 
stage T  N M 10-year survival  (+/- SD) 
     
I A T1a N0 M0 87.9 +/- 1.0 
 
B 
 
T1b 
T2a 
N0 
N0 
M0 
M0 
83.1 +/- 1.5 
79.2 +/- 1.1 
II 
 
A 
 
T2b 
T3a 
N0 
N0 
M0 
M0 
64.4 +/- 2.2 
63.8 +/- 1.7 
 
B 
 
T3b 
T4a 
N0 
N0 
M0 
M0 
50.8 +/- 1.7 
53.9 +/- 3.3 
 C T4b N0 M0 32.3 +/- 2.1 
III 
 
A 
 
T1-4a 
T1-4a 
N1a 
N2a 
M0 
M0 
63.0 +/- 4.4 
56.9 +/- 6.8 
 
B 
 
 
 
 
T1-4b 
T1-4b 
T1-4a 
T1-4a 
T1-4a/b 
N1a 
N2a 
N1b 
N2b 
N2c 
M0 
M0 
M0 
M0 
M0 
37.8 +/- 4.8 
35.9 +/- 7.2 
47.7 +/- 5.8 
39.2 +/- 5.8 
- 
 
C 
 
 
Any  
 
 
N1b 
N2b 
N3 
M0 
M0 
M0 
24.4 +/- 5.3 
15.0 +/- 3.9 
18.4 +/- 2.5 
IV 
 
 
 
Any 
 
 
Any 
 
 
M1a 
M1b 
M1c 
15.7 +/- 2.9 
2.5 +/- 1.5 
6.0 +/- 0.9 
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2.1.5 Melanoma therapy 
The primary treatment for melanoma is surgical excision of all tumor material 
(primary tumor and metastases). For patients with resected stage I melanoma this 
treatment is often curative (80%-90% of patients with stage I melanoma survive for 
10 years). To ensure complete removal of the primary tumor, it has to be removed 
with adequate surgical margins (Table 3). 
Table 3: Recommended excision margins for melanoma 
Tumor thickness  Excision margin 
In situ (tumor has not penetrated basement membrane) 0.5 cm 
< 2 mm 1 cm 
> 2 mm  2 cm 
 
Sentinel LN dissection for the detection of micrometastases may be performed in 
patients with primary tumors that display poor prognostic factors (tumor thickness > 
1mm, ulceration, vertical growth). When micrometastases are found in the sentinel 
LN specimen, radical LN dissection is recommended since 5-12% of affected 
patients have involvement of non-sentinel nodes. Radical LN dissection is also 
standard therapy if LN macrometastases are identified clinically.1 
Although surgery is the preferential treatment for melanoma, complete removal is not 
always possible due to extension and localization of the tumor/metastases or the 
patient´s condition. In this case primary tumors of the lentigo maligna type, regional 
LN metastases and skin metastases may also be controlled by radiation therapy. 
Further, radiation therapy has an important role in the palliation of bone and brain 
metastases.1  
Chemotherapy with cytotoxic agents is used primarily in a palliative mode, aiming at 
prolongation of patient survival and the reduction of tumor burden to ease symptoms 
in stage IV melanoma patients with little chance for cure. With dacarbazine (DITC), 
the best established monotherapy agent, objective remission (>50% reduction in 
tumor mass) can be achieved in 5.3-28.6% of patients. Comparable remission rates 
can be achieved with both IFN-α and IL-2.1 The combination of different cytotoxic 
agents (polychemotherapy) and the combination of cytotoxic agents and cytokines 
(chemoimmunotherapy) could delay the development of drug resistance. These 
combination therapies have been shown to increase the response rate but at the cost 
of higher toxicity. It also appears that they do not significantly affect overall survival.1   
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Spontaneous tumor regression has been observed more frequently in melanoma 
than in most other cancers.32-35  This indicates that melanocytic malignancies may be 
particularly susceptible to effector mechanisms of the immune system. Therapies 
aiming at enhancement of anti-melanoma immunity could therefore be effective 
against this type of cancer. 
 
Patients with no evidence of metastases but at high risk for tumor spread (stage II 
and stage III) may benefit from adjuvant therapy. IFN-α (Roferon®-A, IntronA®) can 
be given as an adjuvant to stage IIB and stage III melanoma patients after resection 
of the primary tumor (Table 4). A meta-analysis of 14 randomized controlled trials 
assessing the efficacy of adjuvant IFN-α in high risk stage II and III melanoma 
patients revealed a statistically significant benefit of IFN-α on disease-free and 
overall survival.5 As some studies indicate, this effect may be more pronounced in 
patients receiving high-dose IFN-α.36, 37  
Another cytokine, Interleukin-2 (IL-2), has been shown to be beneficial for patients 
with metastatic melanoma. An analysis of eight clinical trials between 1985 and 1993, 
involving 270 patients with metastatic melanoma receiving high-dose IL-2, found that 
16% of the patients responded to this treatment.38 IL-2 was approved by the FDA for 
the therapy of metastatic melanoma in 1998. Studies using a variety of other 
cytokines and immunostimulatory agents (Bacille Calmette Guerin – BCG, IFN-γ) in 
an adjuvant setting have shown no significant efficacy.1 
Table 4: Dosage schedules for adjuvant therapy of melanoma with interferon-α. (s.c.: 
subcutaneous; i.v: intravenous, adapted from Garbe et al., 2010)1  
Schedule Dose Frequency Duration Indication 
Low dose 3 MIU (s.c.) Days 1, 3, and 5, 
every week 
18 months Stages II-III 
High dose     
Initiation 20 million IU/m2 
intravenous (i.v.) rapid 
infusion 
Days 1–5 every 
week 
4 weeks Stage III 
Maintenance 10 million IU/m2 
subcutaneous (s.c.) 
Days 1, 3 and 5 
every week 
11 months Stage III 
 
In certain patients, cutaneous melanoma metastases and lentigo maligna melanoma 
have also been shown to respond to topical treatment with IMQ, a synthetic TLR 7/8 
agonist.3, 4  
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Antibodies that block inhibitory immunological pathways may also enhance anti-
melanoma immunity. Ipilimumab, an antibody targetet at Cytotoxic T-Lymphocyte 
Antigen 4 (CTLA-4) has been shown to improve overall survival of patients with 
metastatic melanoma and has recently been approved by the FDA for the treatment 
of late-stage melanoma.39, 40 
There is also strong evidence that the transfer of ex vivo expanded tumor-infiltrating 
T cells can induce regression of melanoma, probably via CD8+ T cell-mediated 
cytotoxicity.41-43    
A new class of drugs, specifically targeting products from genes that are frequently 
mutated in melanoma such as BRAF and NRAS, has been shown in clinical trials to 
significantly improve progression-free survival when compared to DITC (for a review, 
see Eggermont et al., 2011).44 These substances may be of great value in the future 
of melanoma therapy but additional strategies will be needed to successfully treat 
advanced melanoma. 
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2.2 Interferon-α  
Type I IFNs were first described in 1957 by Isaacs and Lindenmann for their ability to 
interfere with viral replication in cell culture.45 Later, it was discovered that they have 
a very important role in both antiviral and anticancer immunity, due to their ability to 
inhibit cell growth and induce apoptosis in malignant and virally infected cells and 
their anti-angiogenic and immune-stimulatory properties.7, 9, 46 
Interferon-α (IFN-α) is used as an adjuvant treatment in high-risk stage IIB and stage 
III melanoma patients after surgical resection of the primary tumor (see 2.1.5). It is a 
member of the type I IFN family, a group of cytokines with great stuctural homology. 
All type I IFNs are encoded by a single gene cluster on chromosome 9 in humans 
and chromosome 4 in mice.47, 48 In humans they include 13 subtypes of IFN-α (IFN-
α1, -α2, -α4, -α5, -α6, -α7, -α8, -α10, -α13, -α14, -α16, -α17 and -α21), IFN-β, IFN-ε, 
IFN-κ and IFN-ω.47 They all are induced by similar mechanisms and trigger similar 
but not identical responses, depending on their differential affinities to the subunits of 
their common receptor.49  
 
This chapter will provide a review of type I IFN signaling. Since the present study 
focuses on the role of IFN-α in melanoma therapy, the anti-cancer activity of this 
cytokine and its role as an adjuvant in melanoma therapy will be discussed in depth. 
2.2.1 The type I IFN signaling network 
Most cell types can produce type I IFN when properly stimulated. In immune cells, 
induction of type I IFN expression requires the engagement of immunological pattern 
recognition receptors (PRR), such as toll like receptors (TLRs) 3, 4, 7, 8 and 9.50, 51  
Somatic cells mainly produce type I IFN in response to viral infection. They sense 
viral nucleic acids via cytoplasmatic sensors such as DAI and RIG-1.52, 53 Sensing of 
viral nucleic acids is followed by the phosphorylation of interferon regulatory factors 
(IRFs).50-55 These transcription factors regulate the expression of the IFN genes.  
Most cell types constitutively express IRF-3 which, upon activation, translocates into 
the nucleus and induces the transcription of IFN-β (Figure 4). Via a positive feedback 
loop active type I IFN signaling then induces the production of IRF-7, the transcription 
factor required for efficient IFN-α expression and for boosting the expression of IFN-
β.56 PDCs, however, constitutively express IRF-7 which allows for the rapid 
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production of large amounts of IFN-α upon recognition of viral nucleic acids via TLR 7 
and 9 (see 2.5.2.1).  
The most thoroughly studied pathway induced by type I IFNs is the JAK-STAT 
pathway. It involves the activation of gene expression by signal transducers and 
activators of transcription (STATs) upon Janus family tyrosine kinase (JAK)-mediated 
phosphorylation.57, 58 All type I IFNs signal via the IFN-α receptor (IFNAR) on the cell 
surface, a heterodimer formed by two peptide chains, IFNAR1 and IFNAR2.47 The 
intracellular domains of the receptor subunits are associated with the Janus kinases 
(JAKs) Tyk2 (IFNAR1) and Jak1 (IFNAR2). IFN-α binding leads to heterodimerization 
of IFNAR1 and IFNAR2 and cross-phosphorylation of Jak1 and Tyk2.59 This activates 
the kinase activity of Jak1 and Tyk2 which then phosphorylate the receptor subunits 
to provide a docking platform for SH2-domain-containing STAT proteins.59, 60 These 
proteins are also phosphorylated by Jak1 and Tyk2, which allows them to form 
homo- or heterodimers and translocate into the nucleus where they act as 
transcriptional activators on genes containing an IFN-γ-activated site (GAS) in their 
promoter region.61 Another important transcription factor formed by activated STATs 
is the IFN-stimulated gene factor 3 (ISGF3). This complex is formed by a STAT1/2 
heterodimer and IRF9. It activates the transcription of genes controlled by an 
interferon-stimulated response element (ISRE).62  
Other pathways required for full transcriptional activation of interferon-stimulated 
genes (ISGs) which are induced by IFN-α include the phosphatidyl-inositol 3-kinase 
(PI3K) and p38 mitogen-activated protein kinase (MAPK) pathways (Figure 4, right 
side).61, 63 
Most somatic cells express IFNAR,64 but they respond to IFN signaling in very 
different ways. Depending on the cell type and additional factors, such as signals 
from other immunological pathways, ISGs are differentially activated. Thus, IFN-α 
can elicit various effects, including inhibition of proliferation and induction of 
apoptosis in malignant and virally infected cells as well as stimulation of innate and 
adaptive immunity (Table 5, Figure 4).9, 45, 46, 65-73 
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Table 5: Effects of type I IFNs 
Target Type Source  
Inhibition of proliferation Sangfelt et al., 19977  
Grimley et al., 199874  
Induction of apoptosis Thyrell et al., 2002, 20048, 75 
Sangfelt et al., 19977 
Sensitization to apoptosis-inducing drugs Sabaawy et al., 199976  
Antiangiogenic 
 
Sidky et al., 198746 
Indraccolo et al., 201077 
 Anti-Tumor 
Increased MHC class I expression Makridis et al., 199478  
Yang et al., 200479 
 
Induction of apoptosis in infected cells Tanaka et al., 199871 
 
Increased MHC class I expression Makridis et al., 199478  
Yang et al., 200479 
 
Antiviral 
Inhibition of viral life cycle Isaacs et al., 195745 
Der et al., 199573 
 
Stimulation of immunity NK cell activation; DC differentiation, 
maturation and migration; enhanced 
phagocytosis by macrophages; B cell 
isotype switching; promotion of TH1-
response; Promotion of CD8+ T cell 
effector function and survival 
Hervas-Stubbs et al., 20119 
(review article) 
BACKGROUND - Interferon-α 
 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IF
N
AR
IR
F9
IS
G
F3
STAT2
STAT1
P PP PPP PP IR
F9
STAT2
STAT1
P P IR
F9P PP PPP PP
IS
RE
IR
F9
STAT2
STAT1
P P IR
F9
P PP PPP PP
STAT1
STAT1
P P
P
P
P PP PPP PP
PP
PP
G
AS
STAT1
STAT1
P P
P
P
P PP PPP PP
PP
PP
STAT1
STAT1P PP PPP PP
STAT1
STAT1
P PP PPP PP
G
AS
STAT1
STAT1
P PP PPP PP
N
u
cl
eu
s
VA
V
RA
C1
-
G
D
P
RA
C1
-
G
D
P
R
AC
1-
G
TP
R
AC
1-
G
TP
M
AP
KK
K
M
AP
KK
3/
6
p3
8
IF
N
AR
IF
N-
α
/β
Cy
to
pl
a
sm
LP
S
TL
R
4
Vi
ru
s
ds
D
N
A
ds
R
N
A
RI
G
-
1
M
D
A-
5
AI
M
2
D
AI
AI
M
2
D
AI
IR
F3
/7
TL
R
3
ds
R
N
A
TL
R7
/8
s
sR
N
A
TL
R
9
ds
D
N
A
IF
N
-
α
/β
m
R
N
A
Tr
a
n
s
la
tio
n
PP
PK
C-
δ
p1
10
p8
5
p1
10
p8
5
IF
N
AR
PI
3K
M
TO
R
Tr
an
s
la
tio
n
+
Su
rv
iv
a
l
+
+
+
p3
8
Ce
ll
gr
o
w
th
+ MA
PK
AP
2
+
STAT1
STAT2
STAT1
PK
C-
δ
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IR
F3
/7
+- +-
Ac
tiv
a
tio
n
o
f v
a
rio
u
s
tr
an
s
cr
ip
tio
n
fa
ct
o
rs
IF
N
α
/β
IF
N
α
/β
P
P
TYK2
JAK1
IF
N
α
/β
PP
PP
IF
N
α
/β
IF
N
α
/β
P
P
TYK2
JAK1
IF
N
α
/β
PP
PP
IF
N
α
/β
IF
N
α
/β
P
P
TYK2
JAK1
IF
N
α
/β
PP
PP
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
α
/β
IF
N
-
α
-
pr
o
du
ci
n
g
ce
ll
re
sp
o
n
di
n
g
ce
ll
BACKGROUND - Interferon-α 
 18 
Figure 4 (previous page): The type I IFN signaling network. Overview of signals leading to type I 
IFNs induction (left side) and signaling pathways triggered by type I IFN (right side). Immune cells 
produce type I IFN upon sensing viral nucleic acids via endosomal TLR3/7/8/9 or extracellular 
bacterial lipopolysaccharides via TLR4 on the cell surface. Type I IFN production by somatic cells is 
dependent on cytoplasmatic sensors of infection such as AIM2 and DAI (dsDNA) or RIG-1 and Mda-5 
(dsRNA). These signals lead to the activation of NFΚB and IRFs, which translocate into the nucleus 
and activate the transcription and secretion of type I IFNs.  
All type I IFNs bind to IFNAR, the intracellular domains of which are constitutively associated with the 
Janus family tyrosine kinases JAK-1 and TYK-2. JAK-1 and TYK-2 cross-activate each other upon 
type I IFN binding to IFNAR and dimerization of the receptor subunits. Subsequently, they 
phosphorylate the intracellular domains of IFNAR whereupon STATs associate with the 
phosphorylated receptor subunits. This brings them in close proximity to the receptor-associated 
Janus kinases, leading to their activation. Upon phosphorylation, STATs can form homo- or 
heterodimers which translocate into the nucleus where they bind to GAS sites in the promoter region 
of various ISGs and activate the transcription of these genes (only the STAT1 homodimer is depicted 
in this figure). The STAT1/STAT2 heterodimer can associate with IRF9, forming the transcription 
factor ISGF3 which can also pass the nuclear membrane and activates the transcription of genes 
containing an ISRE in their promoter. Another target of type I IFN signaling is phosphatidyl-inositol 3-
kinase (PI3K). After receptor engagement, the catalytic subunit of PI3K is activated via an adaptor 
protein which leads to an additional phosphorlyation of STAT1. This is required for full transcriptional 
activation of GAS-controlled ISGs by STAT1 homodimers. Further, PI3K signaling can also promote 
apoptosis or survival in a cell type-dependent manner and enhance mRNA translation via the 
activation of mTOR.61, 80 The p38 MAPK pathway also has a role in IFN-α-mediated signaling. After 
IFN-α-dependent activation, Jak1/Tyk2 can mediate the phosphorylation of guanine-nucleotide 
exchange factors (GEFs), particularly VAV, resulting in the exchange of GDP for GTP in RAC1 and 
possibly other small GTPases. This drives the activation of a MAPK cascade ultimately leading to the 
phosphorylation of p38.61, 81 Downstream of p38 effector kinases like MAPKAP2 and a variety of 
transcription factors are activated and regulate ISG expression on transcriptional as well as post-
transcriptional levels.61, 82-87 
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2.2.2 Anticancer effects of IFN-α  
IFN-α has been shown to exert both direct and indirect antitumor effects. It is 
currently used in the therapy of various solid and haematologic tumors, including 
hairy cell leukemia, follicular non-Hodgkin's lymphoma, renal cell carcinoma, AIDS-
related Kaposi's sarcoma and melanoma.88  
 
Direct effects on cancer cells: 
In cell culture, IFN-α is able to directly inhibit cancer cell proliferation and induce 
apoptosis in malignant cells or sensitize them to other apoptosis-inducing 
chemotherapeutic drugs (e.g. 5-fluorouracil and doxorubicin).7, 8, 74, 76, 89-91 IFN-α also 
enhances MHC class I expression on most cells, facilitating MHC class I-restricted 
antigen presentation to CD8+ T-cells.78, 79 
 
Indirect anticancer effects 
IFN-α also exerts indirect anticancer effects. It can cause hypoxia and necrosis in 
tumors due to its antiangiogenic properties.77  Further, it stimulates innate and 
adaptive immune responses.  
Activating effects of IFN-α on the innate immune system include the promotion of DC 
differentiation and activation92-94 and NK cell effector function.95 The adaptive 
immune system is also affected: IFN-α pushes CD4+ T cells toward the TH1  
phenotype96 and promotes the effector function of CD8+ T cells97, 98 as well as the 
survival, proliferation and isotype switching in B cells (Table 5).99-102 
Many cells, including B cells,103 T cells,104 NK cells105 and pDCs,14 express TRAIL in 
response to IFN-α stimulation.14, 103-105 The relevance of this protein in tumor 
immunity is discussed in more detail in chapter 2.4.3.  
.  
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2.2.3 Anti-melanoma activity of adjuvant IFN-α  
In 2010, Mocellin et al. published a meta-analysis of 14 randomized controlled trials 
assessing the efficacy of adjuvant IFN-α in high risk stage II and III melanoma 
patients.5 A total of 8122 patients were enrolled in these trials, 4362 of which were 
allocated to the IFN-α arm. Whilst previous studies, covering smaller numbers of 
patients, had only found a significant increase in disease-free survival and trend 
toward an increase in overall survival, this study revealed a statistically significant 
benefit of IFN-α on both disease-free and overall survival.  
Many of the potential anti-tumor mechanisms mentioned in 2.2.2 might contribute to 
the observed clinical benefit from adjuvant IFN-α therapy. This benefit appears to be 
attributable to direct anti-tumor effects as well as immunostimulatory effects. A better 
understanding of the mechanisms underlying the efficacy of IFN-α will reveal new 
strategies to maximize its positive effects whilst minimizing its systemic side effects. 
 
In vitro, IFN-α has been shown to reduce proliferation and increase MHC class I 
expression in human melanoma cells.106 Some human melanoma cell lines 
underwent apoptosis when treated with type I IFN, particularly IFN-β.107 IFN-β was 
also shown to sensitize melanoma cells to TRAIL.108 Further, the production of 
vascular endothelial growth factor (VEGF) was repressed in melanoma cells in the 
presence of IFN-α, indicating a decreased angiogenic capacity.109 
IFN-α was also shown to promote NK cell activity and decrease metastasis in murine 
melanoma models.110, 111 
Several immunologic changes were observed in human melanoma patients receiving 
IFN-α. Already in 1985, Hersey and colleagues reported an increase in the 
CD4+/CD8+ T lymphocyte ratio in the blood and an enhanced cytotoxic activity of NK 
cells against a melanoma target cell line during IFN-α treatment in patients with 
metastatic melanoma.112 One study performed by Ascierto et al. in 22 melanoma 
patients with different disease stages, showed that before IFN-α therapy the levels of 
blood regulatory T cells (Tregs) were significantly elevated in melanoma patients 
compared with healthy controls. This might be associated with a repression of an 
anti-melanoma immune response. Upon high dose IFN-α treatment, a trend toward a 
decrease in Treg levels was observed.113  
Another report shows that in melanoma patients receiving adjuvant IFN-α therapy 
serum levels of angiogenic and growth factors (VEGF, epidermal growth factor, and 
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hepatocyte growth factor) are decreasing during treatment whereas the levels of IP-
10, a IFN-γ-inducible protein with antiangiogenic and chemoattractant properties 
(recruitment of monocytes/ macrophages, NK cells, T cells and DCs) are significantly 
raising.114  
The lymphocytic infiltrate in the tumor also seems to be affected by IFN-α. An 
increase in endotumoral CD4+ T cells, CD11c+ mononuclear cells and CD86+ cells 
and a slight decrease in CD83+ cells (both markers of DC activation) were observed 
in a study comparing biopsies of LN melanoma metastases before and after 4 weeks 
of IFN-α therapy. These effects were more pronounced in patients with clinical 
response.115 The biopsies were also examined immunohistochemically for changes 
in tumor cell proliferation, angiogenesis and apoptosis but no significant differences 
were found. 
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2.3 Imiquimod 
IMQ is a small molecular weight TLR7/8 ligand of the imidazoquinoline family. It has 
been approved under the name Aldara® by the FDA for topical treatment of 
anogenital warts, actinic keratoses and superficial BCC.116 Interestingly, results from 
studies conducted so far show that this immune response modifier also has great 
therapeutic potential against melanoma.1, 4, 117, 118  
The following chapter will present an overview of the mode of action of IMQ. Since 
the role of IMQ in melanoma therapy was investigated in this study, special interest is 
paid to the anti-melanoma activity of this drug. 
2.3.1 Mode of action 
The presence of nucleic acids in endosomal compartments presents a danger signal 
for the innate immune system. DNA and RNA do not normally occur in this 
localization, except during infection or after uptake of cellular debris from the 
extracellular space. The endosomal TLRs 3, 7, 8 and 9 can recognize these 
molecules (TLR3 – double stranded RNA, TLR7/8 – single stranded RNA, TLR9 – 
unmethylated CpG DNA) and initiate the transcription of cytokines that modulate the 
immune response.119, 120  
The structure of IMQ resembles that of the purine bases of nucleic acids, particularly 
adenine (Figure 5).121 This allows for its recognition via TLR 7 and 8. Upon ligand 
binding, TLR7/8 activate the transcription factor NFκB and IRFs via the adaptor 
protein MyD88, leading to the production of proinflammatory cytokines.119  
IMQ has been shown to induce the production of IFN-α, TNF-α, IL-1α, IL-1β, GM-
CSF, G-CSF, MIP-1α and IL-1 receptor in human PBMCs in vitro.122 In DCs, IMQ 
treatment leads to maturation.14, 123-125 However, particular DC subsets are 
differentially activated in terms of cytokine production and the expression of cytotoxic 
molecules. CD11c+ myeloid dendritic cells (mDCs) produce IL-12 and granzyme B 
and perforin whereas pDCs excrete large amounts of IFN-α and express TRAIL when 
stimulated with IMQ in vitro (Figure 6).12, 126  
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Figure 5: IMQ and the purine bases adenine and guanine. IMQ and purine bases share a very 
similar chemical structure.  
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Figure 6: Different response of pDCs and mDCs to stimulation with IMQ. In pDCs, IMQ activates 
TLR 7. Subsequently, IRF7 is activated via the adaptor protein MyD88. This transcription factor is 
expressed constitutively only in pDCs, leading to the production of large amounts of IFN-α. Stimulation 
of mDCs results in activation of NFΚB and the expression of proinflammatory cytokines such as IL-12. 
Both cell types express cytotoxic molecules in response to IMQ stimulation in vitro. PDCs produce 
TRAIL whereas mDCs express granzyme B and perforin.  
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One study indicates that in TLR7/8 negative cell lines (Jurkat, K562, MeWo), IMQ 
may also act in a TLR-independent fashion via interaction with adenosine receptor 
signaling and induce the expression of proinflammatory cytokines such as TNFa, IL-
1β, IL-6, and IL-8.127 
 
IMQ has antiviral properties in vivo, as first demonstrated in a guinea pig model of 
herpes simplex virus (HSV) infection. Intravaginal administration of the drug was 
100% protective of primary disease and also significantly reduced disease 
recurrence.128, 129  
Several studies also demonstrate the antitumoral properties of IMQ against 
superficial cutaneous malignancies. Regression of various cutaneous tumors such as 
BCC, squamous cell carcinoma (SCC), Bowen´s disease and cutaneous melanoma 
have been observed upon topical IMQ treatment. 12, 130-132 
The anti-tumor effect of IMQ appears to be associated with its immune-activating 
properties. In 2007, Wolf et al. reported that the inflammatory infiltrate in cutaneous 
tumors (BCC, SCC, melanoma in situ and melanoma metastases) treated with IMQ 
contains increased numbers of T lymphocytes and pDCs.11 This phenomenon was 
associated with tumor regression. A study by Stary et al. also showed that in BCC 
and melanoma, tumor regression upon IMQ treatment was associated with an influx 
of pDCs.12 
2.3.2 IMQ in melanoma therapy 
Although its use in melanoma therapy is experimental, IMQ has very efficiently been 
used to treat cutaneous melanoma lesions in some patients. Complete remission of 
lentigo maligna melanoma could be achieved in 75-88% of patients treated with 
Aldara® cream.1 Complete or partial responses of cutaneous melanoma metastases 
have also been observed with this therapy.4, 117, 118  
These positive effects of IMQ have mainly been attributed to indirect anti-cancer 
activity via stimulation of anti-melanoma immunity but direct effects on the tumor 
have also been proposed. 
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Indirect anticancer effects of IMQ: 
In mouse skin, topical IMQ treatment leads to an influx of pDC-like cells and a local 
increase of IFN-α and TNF-α, two cytokines with known antitumoral properties. 10, 133 
Topical treatment with IMQ after cryosurgery enhanced the systemic immunity 
against new melanoma challenges in a B16 murine melanoma model.134 
In humans, the treatment of melanoma lesions with IMQ leads to local inflammation. 
An increase in T cells (both CD4+ and CD8+), TIA-1+ (T-cell-restricted intracellular 
antigen-1) and granzyme B+ cytotoxic cells and pDCs in the tumor infiltrate.11 
Enhanced numbers of CD4+ T cells in the sentinel LNs were also reported.11, 135 In 
mice too, melanoma regression after IMQ treatment was associated with an influx of 
pDC-like cells.11, 133 Expression of cytotoxic molecules was not assessed in these 
studies but analysis of a similar infiltrate in human BCC upon IMQ treatment revealed 
that intralesional pDCs expressed TRAIL.12 These findings indicate that pDCs might 
have a direct cytotoxic effector function in IMQ-treated cutaneous malignancies (see 
2.5.2.1). 
 
Direct anticancer effects of IMQ: 
IMQ might also affect melanoma cells themselves. High doses of IMQ have been 
shown to induce apoptosis in melanoma cell lines in vitro in a TLR-independent 
fashion.6 In murine macrophages and human BCC cells, IMQ can also induce 
autophagy.136, 137 Whether the latter applies to melanoma too, remains to be 
elucidated. 
 
Many patients with benign or semi-malignant skin cancers clearly benefit from topical 
IMQ treatment.130, 138, 139 Future studies will reveal whether IMQ could also serve as a 
non-invasive treatment for superficial melanoma lesions.  
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2.4 TRAIL 
In 1995, Wiley et al. first described a new member of the tumor necrosis factor (TNF) 
family, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).140 Other 
members of this family include TNF-α, TNF-β and Fas ligand. They are capable of 
inducing apoptosis in a broad range of cells via interaction with specific death 
receptors (DRs) but they can also mediate inflammation and the transcription of 
survival factors.119 Among these proteins, TRAIL has the remarkable ability to induce 
apoptosis in tumor cells but not in normal cells.141 This makes it an interesting subject 
for cancer research and a promising candidate for new therapeutic approaches 
against cancer.140  
 
Since the ability of TRAIL to induce apoptosis in melanoma cells was the main focus 
of our work, this chapter will give an overview of TRAIL-induced apoptotic signaling 
and discuss its role in tumor immunity. 
2.4.1 TRAIL and TRAIL receptors 
TRAIL can exist in a trimeric membrane-bound form (memTRAIL) or it can be 
cleaved from the cell surface, probably via cysteine proteases, to form soluble TRAIL 
(sTRAIL).142 In humans, four cellular receptors, TRAIL R1-4 can bind to TRAIL. 
TRAIL R1 and TRAIL R2, also termed death receptors (DR), possess an intracellular 
death domain (DD) that can activate the apoptotic cascade. TRAIL R1 can be 
activated by both memTRAIL and sTRAIL whereas TRAIL R2 signaling is triggered 
by memTRAIL or secondarily crosslinked sTRAIL only.143  
TRAIL R4 has a truncated intracellular domain lacking the DD and TRAIL R3 
completely lacks the intracellular domain. This renders them both incapable of 
transducing an apoptotic signal. They are thought to act as decoy receptors via 
competition for TRAIL binding. Indeed, overexpression of these receptors has been 
shown to be protective against TRAIL-induced apoptosis.144, 145 However, other 
studies show that TRAIL susceptibility is largely independent of TRAIL R3/4 
levels.146, 147  
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2.4.2 TRAIL signaling pathways 
Binding of TRAIL to one of its DRs induces the extrinsic (receptor-mediated) 
apoptotic pathway. This pathway requires the binding of a cytotoxic ligand to a DR on 
the cell surface. Receptor trimerization upon ligand binding leads to a conformational 
change in the intracellular DD of the receptor. Thereby activated, the receptor DD 
can interact with the DD of the adaptor protein FAS-associated death domain (FADD) 
which in turn recruits procaspase-8, forming the death-inducing signaling complex 
(DISC). Within this complex, procaspase-8 is cleaved autoproteolytically into 
caspase-8. This enables it to activate the downstream effector caspase-3 which then 
initiates the apoptotic programme (Figure 7).148, 149  
Some cells require an amplification of the TRAIL apoptotic signal via the intrinsic 
(mitochondrial) apoptotic pathway. The two pathways are linked via caspase-8, which 
can also cleave the pro-apoptotic protein Bid. Truncated Bid induces the formation of 
pores in the outer mitochondrial membrane, causing the release of mitochondrial 
cytochrome-c into the cytosol. This initiates the assembly of the apoptosome, where 
procaspase-9 is cleaved to active caspase-9. Caspase-9 also cleaves procaspase-3, 
providing an amplification loop for the extrinsic apoptotic pathway (Figure 7).149  
Based on the apoptotic pathways involved, type I (extrinsic only) and type II 
(additional activation of intrinsic pathway required) TRAIL-sensitive cells can be 
distinguished.149 It has also been proposed, that the requirement of activation of the 
intrinsic pathway of apoptosis might partially be a dose-dependent phenomenon, 
since the protective effect of blocking the mitochondrial pathway in Jurkat cells was 
limited to low doses of TRAIL.150  
Under certain conditions, such as the inhibition of protein synthesis or a low pH of the 
cell culture medium, TRAIL can also induce necrosis in tumor cells via activation of 
receptor-interacting protein (RIP) kinase.151, 152 It has been suggested that this 
pathway might play a major role in TRAIL-mediated cytotoxicity against solid tumors 
with an acidic microenvironment.151 
An alternative pathway leading to the activation of NFκB and promoting cell survival 
can be activated via TRAIL R1, 2 and 4.153, 154 The balance between apoptotic 
signaling and NFκB activation is thought to be one factor determining TRAIL 
susceptibility. Additionally, a variety of antiapoptotic proteins (cFLIP, XIAP, Bcl-2)155-
158
 can interfere with the apoptotic cascade at different levels to inhibit the activation 
of caspase-3. Such proteins are often overexpressed in tumor cells (eg. FLIP, Bcl-2 
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and Mcl-1 in melanoma), thus limiting the efficacy of apoptosis-inducing drugs. 159, 160, 
161
   
Type II cells
Necrosis
 
Figure 7: Scheme of the TRAIL signaling cascade. Binding of TRAIL to TRAIL R1/2 induces the 
assembly of the death-inducing signaling complex (DISC), the activation platform of caspase-8. Active 
caspase-8 then cleaves the effector caspase-3, initiating the apoptotic programme. In most cells, 
additional activation of the intrinsic pathway is required for the induction of apoptosis. In these cells, 
termed type II cells, active caspase-8 truncates the proapoptotic protein Bid, inducing the release of 
cytochrome c from the mitochondria. This leads to the assembly of the apoptosome, where caspase-9 
is activated. Caspase-9 further promotes apoptosis via the activation of caspase-3. In contrast to 
apoptosis, TRAIL can also induce necrotic cell death via activation of the kinase RIP. Conversely, 
TRAIL R1/2 and TRAIL R4 engagement can also promote cell survival via NFΚB activation. Figure 
adapted from Falschlehner et al., 2007.162  
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2.4.3 The role of TRAIL in anti-tumor immunity 
Not only the selective induction of apoptosis in tumor cells indicates that TRAIL has 
an essential role in tumor immunity. A broad range of human immune cells including 
B cells,103 T cells,104 NK cells,105, 163 and pDCs14, 164 can be induced to express TRAIL 
on their surface when treated with certain immunostimulatory agents, particularly 
IFN-α. TRAIL-mediated cytotoxicity of such stimulated lymphocytes against tumor 
cells has been demonstrated in several in vitro studies. 14, 164-166 
In vivo evidence for the importance of TRAIL in cancer immunity has been generated 
in TRAIL and TRAIL R knockout mice which display increased susceptibility to tumor 
formation and metastasis.167-169 Further, murine liver NK cells that constitutively 
express TRAIL were demonstrated to have a role in the suppression of liver 
metastasis.170, 171 
TRAIL itself is currently being assessed as a potential anti-cancer drug. Results 
obtained in phase I and II clinical trials using recombinant human TRAIL (rhTRAIL) or 
antagonistic antibodies against TRAIL DRs show that these drugs are generally well 
tolerated but the clinical effect is limited (for a review, see Bellail et al., 2009).172 It 
has been shown that tumor cells acquire TRAIL resistance rather quickly when 
cultured in the presence of TRAIL. This might be the reason for the limited efficacy of 
monotherapy with TRAIL-based drugs.173  
Various studies demonstrate that the combination of recombinant human TRAIL 
(rhTRAIL) with other proapoptotic agents or even radiotherapy can have synergistic 
effects or sensitize cancer cells to TRAIL-induced apoptosis.174-178 This indicates that 
TRAIL-based drugs may be more efficient when used in combination with other 
therapies. 
In summary, the current state of knowledge points toward an important function for 
TRAIL in natural and therapy-induced tumor immunity. In the future it may play a 
significant role in the combat against cancer either via the induction of immune cells 
to express TRAIL or as an anti-cancer drug itself.  
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2.5 Dendritic cells 
The following chapter will provide an introduction into DC biology. Since the present 
study aims to assess the cytotoxic potential of pDCs, this particular DC subset is 
discussed in detail. 
2.5.1 Antigen presentation 
DCs are professional antigen presenting cells with the unique ability to induce 
primary immune responses. Immature DCs in the periphery have a high capacity to 
take up antigens from the environment. Within endosomes the antigen is 
proteolytically degraded and loaded onto MHC class II molecules, which are 
recognized only by CD4+ T cells (Figure 8). Activation of CD8+ T cells requires 
antigen presentation via MHC class I molecules, which usually display peptides 
derived from proteins that were generated in the cytoplasm. DCs can also transport 
endosomal antigens into their cytosol, allowing for their presentation to CD8+ T cells 
in the context with MHC class I (cross-presentation).119 
Recognition of pathogens, leading to DC maturation occurs via general pattern 
recognition receptors (e.g. TLRs, C-type lectin receptors). This induces the 
upregulation of costimulatory molecules such as CD83 and CD86 and migration to 
the draining LNs. There, mature DCs present processed antigens to naive T cells, 
leading to their activation. The ability of DCs to activate naive T cells depends on 
their maturation status and the expression of costimulatory molecules. Antigen 
recognition without costimulation causes tolerance rather than immunity. 119, 179 
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Figure 8: MHC class II-restricted antigen presentation by DCs. In contrast to somatic cells, DCs 
are capable of presenting antigen to naive T cells in the context of MHC class II molecules. In the 
periphery, DCs take up extracellular antigens via endocytosis. In endosomes, the antigen is then 
cleaved into small peptides (processed antigen). The processed antigen is then loaded onto MHC 
class II molecules and presented on the cell surface. Via cross-presentation, DCs can also present 
peptides to CD8+ T cells in the context with MHC class I (not shown). Upon activation via pattern 
recognition receptors (e.g. TLRs) DC maturation is induced. Activated DCs migrate to the draining LNs 
where the antigen is presented to naive CD4+ T cells. Interaction of the T cell receptor with a specific 
MHC class II bound antigen in context with stimulation via costimulatory molecules (CD86) leads to T 
cell activation.   
2.5.2 Blood dendritic cells subsets 
DCs are characterized by the expression of MHC class II (HLA-DR) and the lack of 
hematopoietic lineage (Lin) markers (e.g. CD3, CD19, CD14, CD56) on their surface. 
Human blood contains three major Lin-HLA-DR+ subsets: CD34+ precursors, CD303+ 
(blood dendritic cell antigen-2, BDCA-2) plasmacytoid DCs (pDCs) and CD11c+ 
myeloid DCs (mDCs), which can be further divided into subgroups expressing CD1c 
(BDCA-1), CD141 (BDCA-3) and CD16. 180 
DC subsets do not only differ in their expression of surface markers, they also 
express distinct sets of immunological pattern recognition receptors, the best 
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characterized of which are TLRs. The expression of TLRs in pDCs and mDCs is 
summarized in Table 6. 
Table 6: TLR expression in human pDCs and mDCs.126, 181-184 (+: present; -: absent; mRNA: 
reported on mRNA level only; +/-: present in some studies)   
Expression in TLR Ligand localization pDCs mDCs 
   
 
1 bacterial products Cell membrane mRNA + 
2 bacterial products Cell membrane - + 
3 dsRNA Endosomes - + 
4 bacterial products Cell membrane - +/- 
5 bacterial products Cell membrane - + 
6 bacterial products Cell membrane mRNA + 
7 ssRNA Endosomes + +/- 
8 ssRNA Endosomes - + 
9 CpG DNA Endosomes + - 
The differential expression of TLRs indicates distinct functions for different DC 
subsets. MDCs predominantly sense bacterial products via extracellular TLRs and 
TLR signaling results in the activation of NFκB, leading to the secretion of 
proinflammatory cytokines such as IL-6, IL-12 and TNF-α. In contrast, pDCs 
specialize in detecting viral nucleic acids via endosomal TLRs and produce large 
amounts of IFN-α.179 
2.5.2.1 Plasmacytoid dendritic cells 
Although they only account for 0.01-0.05% of PBMCs, pDCs are the primary source 
of type I IFNs.185, 186 This is made possible by the constitutive expression of IRF7, 
rendering the cells capable of producing copious amounts of type I IFN, independent 
of IFNAR-mediated feedback signaling (see 2.2.1).187  
 
Classical functions of pDCs: 
PDCs sense viral nucleic acids via endosomal TLR7 (ssRNA) and TLR9 
(unmethylated CpG DNA) and can initiate a multitude of IFN-dependent and IFN-
independent immunological functions.  
Upon activation pDCs produce large amounts of type I IFN along with other cytokines 
and chemokines including TNF-α, IL-6, IL-8 and CXCL10 (reviewed by Fitzgerald-
Bocarsly et al., 2009).188 Activated human pDCs promote the migration of NK cells 
and activated T cells,189 the maturation of mDCs190 and plasma cells191 in vitro and 
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can also function as antigen presenting cells themselves, albeit less efficiently than 
mDCs.192 Furthermore, pDC-derived type I IFNs can directly interfere with viral 
replication and tumor growth as discussed in 2.2.2.  
 
Cytotoxic  pDCs: 
Interestingly, pDCs have also been found to have cytotoxic functions. Freshly 
isolated pDCs have been shown to express granzyme B. Upon stimulation with 
endogenous or exogenous type I IFN, viruses or synthetical TLR7 and TLR9 agonists 
pDCs also express TRAIL. This enables them to directly exert cytotoxic effector 
functions against tumor cells and virally infected cells (see 2.4.3).12-14, 164, 193   
 
The role of pDCs in tumor immunity: 
The role of pDCs in tumor immunity is not yet clearly understood, but tumor-
infiltrating pDCs have been found in human melanoma,194, 195  breast cancer,196 head 
and neck cancer197 and BCC. 11  
In early stage breast cancer, infiltration with pDCs was associated with decreased 
patient survival,196 which might be due to tolerogenic properties of immature pDCs.192 
 
Several studies indicate that pDCs might have an important role in the efficacy of 
topical IMQ against cutaneous malignancies. In a mouse melanoma model, the 
number of tumor infiltrating pDC-like cells correlated well with the clinical response to 
IMQ.13, 133 A recent study by Drobits et al. further demonstrated that pDCs actively 
participate in melanoma clearence in a mouse melanoma model.13  In humans, pDCs 
were found in the lymphocytic infiltrate of melanoma, squamous cell carcinoma and 
BCC during IMQ treatment.11 Our group has shown that in human BCC tumor 
regression upon topical IMQ treatment was associated with an influx of pDCs that 
expressed TRAIL and that IMQ-stimulated pDCs acquire TRAIL-dependent cytotoxic 
effector functions in vitro.12 The current data suggests that the contribution of pDCs 
to tumor immunity might not only be confined to the production of IFN-α and the 
stimulation of the immune system. PDCs themselves might acquire cytotoxic effector 
functions against tumor cells. To gain a better understanding of this phenomenon 
was an aim of this study. 
MATERIALS AND METHODS - Cell lines and cell culture 
 34 
3 MATERIALS AND METHODS 
All plastic material (multiwell plates, cell culture flasks, pipet tips) was purchased from 
Eppendorf, Becton Dickinson or Corning Incorporated, if not stated differently. 
3.1 Cell lines and cell culture 
All working steps with cell lines were carried out under sterile conditions in a laminar 
air flow hood.  
 
Standard cell culture medium:  
RPMI 1640 (Invitrogen, Cat. No.: 52400-041) 
10% v/v FCS (Invitrogen, Cat. No.: 10500-064) 
1% v/v Penicillin-Streptomycin (Invitrogen, Cat. No.: 15070-063), 
containing 5,000 IU of penicillin (base) and 5,000 µg of streptomycin 
(base) per ml.  
 
Melanoma cell lines 
Four established malignant melanoma cell lines from American Type Culture 
Collection (ATCC) or Wistar Institute (SkMel2, SkMel28, MeWo, WM793) and four 
melanoma cell lines generated from metastases from stage III and IV melanoma 
patients by Dr. F. Koszik (Division of Immunology, Allergy and Infectious Diseases, 
Department of Dermatology, Medical University of Vienna), Pat1-4, were used in this 
study. The melanoma identity of the cell lines was confirmed prior to this study by 
assessing the intracellular expression of the melanoma markers HMB45, MelanA and 
S100 using flow cytometry. 
 
Table 7: List of melanoma cell lines, patient information and split ratio. N.a.: information not available. 
Cell line Patient age Patient gender Metastatic site  Split ratio Catalog number 
SkMel2 60 Male Skin 1:8 ATCC HTB-68 
SkMel28 51 Male N.a. 1:6 ATCC HTB-72 
MeWo 78 Male Lymph node 1:6 ATCC HTB-65 
WM793 N.a N.a N.a 1:6 Wistar Institute 
Pat1 52 Female Dermal 1:8 - 
Pat2 30 Male Illeum 1:6 - 
Pat3 57 Male Ascites 1:4 - 
Pat4 53 Female Axilla 1:6 - 
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Jurkat cells 
Jurkat cells are a line of immortalized T-lymphocytes established from the peripheral 
blood of a 14-year old boy with T cell leukemia. Because of their susceptibility to 
TRAIL 198, they served as a model cell line for TRAIL-mediated killing in this study.  
3.1.1 Harvesting/passaging of melanoma cells 
Trypsin/EDTA 
Trypsin/EDTA (Invitrogen, Cat.No: 14190-169) 
PBS/EDTA 0.02% 
Dulbecco´s Phosphate buffered saline (Invitrogen, Cat. No.: 14190-169) 
0.02% w/v EDTA  
 
Cells were passaged by trypsinization when about 90% confluent. Medium was 
removed completely and 5-10ml Trypsin/EDTA (Invitrogen, Cat.No: 14190-169) were 
added. After detachment  from the culture flask surface, the cells were transferred 
into a 50ml falcon tube and washed once with standard medium. After resuspension 
in 10ml standard medium and depending on the split ratio (Table 7), 2-5ml of the cell 
suspension were seeded into a new 75cm2 cell culture flask containing 15-18ml of 
culture medium. 
In order to avoid proteolytic cleavage of surface antigens, the cells were harvested 
using PBS/EDTA for extracellular FACS staining. This procedure was carried out like 
trypsinization but with a longer incubation time before cell detachment. 
3.1.2 Passaging of Jurkat cells 
Jurkat cells were passaged every 2-3 days by removing 15ml of cell suspension and 
adding 15ml of fresh culture medium. 
3.1.3 Freezing and thawing 
Freezing medium:  
FCS (Invitrogen, Cat. No.: 10500-064) 
10% v/v DMSO (Merck, Cat. No.: 1.09678.0100) 
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To ensure consistent quality of the cells, frozen stocks of all cell lines were prepared 
and cells were discarded after a maximum of two months in culture. 
Cells grown to confluency in four 225cm2 culture flasks were trypsinized, pooled and 
washed once in sterile PBS before they were resuspended in freezing medium to a 
final concentration of 1x106-10x106 cells/ml. Aliquots of 1ml were filled in Cryo.S 
cryotubes (Greiner Bio One, Cat. No.: 122263) and cooled down to -80°C over night 
in a freezing container (Qualifreeze, Qualilab). The next day, cells were transferred to 
liquid nitrogen.   
Cells were thawed in a 37°C waterbath, washed once in culture medium and seeded 
to 75cm2 polypropylene plastic flasks in a total of 20ml culture medium. Before they 
were used in experiments, cells were passaged at least once. 
3.1.4 Determination of cell number 
After harvesting, cells were resuspended thoroughly in culture medium, and 10µl of 
cell suspension were mixed with 10µl of trypan blue (Sigma, Cat.No.: T8154). 10µl of 
this solution were then loaded on a disposable C-Chip hemacytometer (Digital Bio, 
Cat.No.: DHC-N01). Cells in all four squares were counted and the average value 
calculated. The result was multiplied with 2x104 to obtain the number of cells per ml 
of the suspension.  
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3.2 DAPI staining for mycoplasm contamination 
Mycoplasma are a genus of small intra- or extracellular bacteria often found as 
contaminants in cell culture. Due to their small size, they can pass through standard 
filters. Also, many strains are resistant to antibiotics commonly used in cell culture. 
Infection with mycoplasma can inhibit cell proliferation by nutrient withdrawal and, 
more importantly, it can also affect cell physiology and thus influence the outcome of 
an experiment. Cell cultures therefore have to be tested for contamination with these 
bacteria.199 To this aim the cells were stained with DAPI (4’,6-Diamidine-2’-
phenylindole dihydrochloride) which intercalates in the nuclear DNA of eukaryotic 
cells as well as mycoplasma DNA. In contaminated samples, mycoplasma appear as 
small spots of extranuclear fluorescence in and around the cells. 
3.2.1 Experimental procedure 
Methanol: 
Methanol (Fisher Scientific, Cat. No.: M/4000/15) 
 
DAPI stock solution: 
10mg DAPI (Roche, Cat. No.: 10 236 276 001) 
10ml ddH2O (B. Braun Melsungen AG, Cat. No.: 0082479E) 
 
DAPI Stock solution was diluted 1:1000 in methanol before use 
(DAPI/methanol, final concentration: 1µg/ml). 
 
Cells were grown for 2-3 passages in antibiotic-free medium in 25cm2  culture flasks 
and then seeded on Chamber slides (Lab-Tek, Cat. No.: 70379-42). When 
confluency reached 50%-70% the medium was removed and chambers were rinsed 
once with DAPI/methanol. Cells were then covered with DAPI/methanol and 
incubated for 15min at 37°C in the dark. After washing once with pure methanol the 
chambers were removed and a coverslip was placed on the sample using 
PermaFluor (Thermo Scientific, Cat. No.: TA-006-FM) as mounting medium. Within 
the next days, slides were examined for mycoplasm contamination under a Zeiss 
Axiophot fluorescence microscope.  
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3.3 Preparation of blood cells 
3.3.1 Preparation of PBMC 
PBMCs were prepaired from buffy coats (Austrian Red Cross, Cat. No.: E2776V00). 
Buffy coats were diluted in PBS to a final volume of 280ml. 35ml of this solution were 
carefully layered over 15ml of Ficoll Paque™ Plus (GE Healthcare, Cat. No.: 17-
1440-03) per 50ml Falcon and centrifuged for 20min at 601xg without break.  
 
Figure 9: Schematic depiction of PBMC isolation using Ficoll Paque™ Plus. After centrifugation 
the components are separated according to their specific densities. PBMCs are located in the 
interphase between Ficoll Paque™ Plus and plasma/PBS. 
 
PBMCs in the interphase were pooled into a new 50ml Falcon tube and washed 
three times (601xg-338xg-601xg). After the last washing step PBMCs were either 
resuspended in MACS buffer for isolation of pDCs or in RPMI 1640 with 10%v/v FCS 
for over night cultivation.        
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3.3.2 Isolation of pDCs 
MACS buffer stock solution 20x: 
PBS 
40mM EDTA 
10% w/v BSA (Sigma, Cat. No.: A9647-500G) 
 
MACS buffer stock solution was diluted 1:20 in PBS and sterile filtered prior to 
use. 
 
PBMCs generated from buffy coats were used for the isolation of pDCs. After the last 
wash, the cells were resuspended in MACS buffer to a concentration of 3x108 
cells/ml.  First the cell suspension was depleted of hematopoietic progenitor cells and 
lineage positive (lin+) cells, such as T cells, B cells, monocytes, macrophages, NK 
cells or granulocytes. To this end the cell suspension was incubated for 15min with 
primary mouse IgG1 antibodies against CD3, CD11b, CD16, CD19, CD34, CD41, 
CD56 and CD235a (Beckman Coulter, Cat. No.: IM1304, IM0190, IM0813, IM1313, 
IM1869, IM0145, IM1844, IM2210). Cells were washed once in MACS buffer (4°C, 
601xg, 10min) and resuspended in MACS buffer at a concentration of 1.25x108 
cells/ml. Subsequently 250µl of Rat Anti-mouse IgG1 MicroBeads (Miltenyi biotec, 
Cat. No.: 130-047-102) were added per ml cell suspension. Following another 
incubation for 15min in the fridge, lin+ cells were immunomagnetically depleted using 
the appropriate amount of CS Columns (Miltenyi Biotec, Cat. No.: 130-041-305). 
Plasmacytoid DCs were isolated from lineage-depleted PBMCs using the CD304 
(BDCA-4/Neuropilin-1) MicroBead kit (Miltenyi Biotec, Cat. No.: 130-090-532) 
according to the manufacturer´s protocol. Purity of isolated pDCs, as assessed by 
flow cytometry, was greater than 95% and contaminations with CD3+, CD14+, 
CD19+ and CD56+ cells were smaller than 1%. 
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3.3.3 Stimulation of blood cells 
IFN-α2a 
Roferon®-A 6x106 IU/ml (Hoffmann – La Roche, Cat. No.: B2070), stored 
at +4°C 
Imiquimod (IMQ) 
Imiquimod 5mg (Invivogen, Cat. No.: tlrl-Imq) 
 
To induce expression of TRAIL, PBMCs or pDCs were stimulated over night with 
different concentrations of Roferon®-A or IMQ or a combination of both reagents. 
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3.4 Flow cytometry 
FACS buffer 
PBS 
1% w/v BSA 
0.1% w/v Azide 
 
The expression of TRAIL, TRAIL receptors and MHC molecules on melanoma cells 
as well as the different subpopulations of PBMCs were assessed using flow 
cytometry.  
The cells were harvested using PBS/EDTA, washed twice in ice-cold PBS and 
resuspended in ice-cold FACS buffer. 2% mouse serum (Dako, Cat. No.: X0910) was 
added to the cell suspension to block unspecific binding of antibodies. Labeled 
antibodies against surface antigens (Table 8) were pipetted into 1.4ml ScreenMates 
tubes (Thermo Scientific, Cat. No.: 4140), and 50µl cell suspension was added to 
each tube. After 15min incubation at 4°C in the dark, cells were washed twice in ice-
cold FACS buffer and antigen expression was analyzed using a 4-colour BD 
FACSCalibur™ flow cytometer.  Expression was considered positive, when the mean 
fluorescence intensity MFI (geo meansample-geo meanisotype) was positive in three 
independent experiments and the mean MFI was greater than one. A mean MFI 
greater than 10 was defined as strong expression. 
 
Table 8: List of antibodies used for flow cytometry 
Antibody Isotype Label Company Cat. No. 
TRAIL mIgG1 PE eBioscience 12-9927-71 
TRAIL R1 mIgG1 PE R&D FAB 347P 
TRAIL R2 mIgG1 PE R&D FAB6311P 
TRAIL R3 mIgG2b PE R&D FAB6302P 
TRAIL R4 mIgG1 PE R&D FAB633P 
HLA-DR mIgG2a FITC BD 347400 
HLA-DR mIgG2a Per-CP BD 347402  
HLA-ABC mIgG2a FITC seroTec MCA81P 
BDCA-2 mIgG1 APC Miltenyi Biotec 130-090-905  
CD83 mIgG1 FITC BD 556910 
CD19 mIgG1 PerCP BD 345790 
CD14 IgG2b FITC BD 345784 
CD3 mIgG1 APC BD 345767 
mIgG1 mIgG1 PE BD 345816 
mIgG2b mIgG2b PE southern biotech 0104-09 
mIgG2a mIgG2a PE BD 349053 
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3.5 Real-time PCR 
All reagents and plastic material used were of PCR quality. 
 
DEPC-treated water: 
0.1ml DEPC (Carl Roth GmbH, Cat. No.: K028.1) 
100ml Aqua bidestillata (Mayrhofer Pharmazeutika GmbH, Cat. No.: 
15.533) 
Reagents were stirred over night at 37°C and autoclaved two times. 50ml 
aliquots were prepared and stored at -20°C. 
  
75% Ethanol: 
37.5ml Absolute Ethanol (Merck, Cat. No.: 1.00983.1000) 
12.5ml DEPC-treated water 
3.5.1 RNA isolation 
1x106-5x106 cells were harvested, washed twice in 1x PBS, resuspended in 1ml TRI 
reagent (Sigma-Aldrich Co., Cat. No.: T9424) and stored at -20°C. For RNA isolation 
samples were thawed on ice and incubated at room temperature for 5min. Then 
200µl chlorophorm (Merck, Cat. No.: 1.02445.0250) were added and samples were 
vortexed for 15sec. After a 2-10min incubation, samples were centrifuged (4°C, 
12000xg, 5min). The aqueous (upper) phase was transferred into a new Eppendorf 
tube and mixed with 500µl isopropanol (Sigma-Aldrich, Cat. No.: 19516). After a 
10min incubation period, samples were centrifuged again (4°C, 12000xg, 10min) and 
the supernatants were discarded. The pellets were washed once in 75% ethanol and 
then air-dried for 5-10min. After dissolving the pellets in 40µl DEPC-treated water, 
the RNA obtained was incubated for 10min at 55°C on an Eppendorf Thermomixer 
5436 heat shaker. RNA concentration was determined using a NanoDrop ND-1000 
Spectrometer (Peqlab). If not used immediately, RNA samples were stored at -80°C.  
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3.5.2 Reverse transcription 
For reverse transcription of isolated RNA, the Applied Biosystems High Capacity 
cDNA Reverse Transcription Kit (Cat. No.: 4374966) was used. 
 
Reaction mix: 
4ng RNA (or maximal 27.4µl)  
1.6µl dNTP mix (25x) 
4µl RT buffer (10x) 
4µl random primers (10x) 
2µl MultiScribe reverse transcriptase 
1µl RNAse inhibitor 
DEPC-treated water was added to a reaction volume of 40µl.  
 
The reaction mix was incubated for 10min at 25°C, followed by 120min at 37°C and 
5min at 85°C in a Perkin Elmer 480 Thermocycler. cDNA samples were stored at 4°C 
(short-term) or -20°C (long-term). 
3.5.3 Real time PCR 
The reaction was carried out on ice. TaqMan Gene Expression Mastermix (Applied 
Biosystems, Cat. No.: 4369510) and Taqman Gene Expression Assays (Applied 
Biosystems, Cat. No.: 4331182, 4351372) were used for real time PCR. 
 
2µl of cDNA per well were mixed with 10µl TaqMan Gene Expression Mastermix (2x), 
1µl TaqMan Gene Expression Assay (20x), and 7µl DEPC-treated water in a 96-well 
PCR plate. After sealing the plate with an optical adhesive film, the plate was 
centrifuged briefly (1min, 234xg) and quantitative PCR was performed using a 
StepOne Plus PCR machine with the following parameters: 
 
Table 9: PCR parameters 
Real-time PCR 
conditions 
1 2 3 (40 cycles) 
Temperature 50°C 95°C 95°C 60°C 
Time 2min 10min 15sec 1min 
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All reactions were run in duplicates. To compare the mRNA levels of TRAIL and its 
receptors within the cell lines, the fold difference (d) between the target gene and the 
reference gene (GAPDH) was calculated using the formula d=2-∆CT (∆CT=difference 
in threshold cycles for target gene and reference gene). 
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3.6 Annexin V/PI staining for apoptosis 
Annexin V is a cellular protein with a binding specificity for phosphatidyl serine 
residues. It can be used to detect inversion of the cell membrane in apoptotic cell 
death. During this process, phosphatidyl serine residues, which are located on the 
inner cell membrane in living cells, are transported to the cell surface. This makes 
them accessible to binding of Annexin V, which can be fluorescently labeled and 
subsequently detected via flow cytometry.   
 
SuperKillerTRAIL™ 0.1mg/ml: 
20µl SuperKillerTRAIL™ (Alexis biochemicals, Cat. No.: ALX-201-115-
C010) 
80µl Killer TRAIL Storage and Dilution Buffer (Alexis biochemicals, Cat. 
No.: ALX-505-005-R500) 
 
10µl aliquots were stored at -80°C. 
 
1x Annexin binding buffer 
4ml Annexin V Binding Buffer, 10X Concentrate (BD, Cat. No.: 556454) 
36ml ddH2O (B. Braun Melsungen AG, Cat. No.: 0082479E) 
 
For Annexin staining, FITC-labelled Annexin V and Propidium Iodide (PI) from the 
Bender MedSystems Apoptosis Detection Kit (Cat. No.: BMS500FI/100CE) were 
used.  
Melanoma cells were seeded to 24-well plates with an expected density of 60-90% 
confluency for the next day and allowed to adhere to the surface over night before 
treatment. The next day, the medium was removed and wells were rinsed to remove 
unattached and dead cells. Then 0.5ml standard medium containing the effector 
agent was added.  
For the evaluation of susceptibility of melanoma cells to TRAIL, standard medium 
containing different concentrations of SuperKillerTRAIL™ (skTRAIL) or the TRAIL 
storage and dilution buffer as mock control were added to the wells and incubated for 
16h. To investigate IFN-α-induced apoptosis, cells were incubated with standard 
medium containing 100-10000U/ml Roferon®-A for 24h. Culture medium with the 
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same volume of PBS served as negative control. The effect of IFN-α-pretreatment on 
TRAIL-induced apoptosis was analyzed using cells that had been pretreated with 
1000IU/ml Roferon®-A for 24h.  
After incubation cells were trypsinized and transferred into a FACS tube. Cells were 
centrifuged and supernatants were removed completely before cell pellets were 
carefully resuspended in 100µl 1x Annexin binding buffer (10x Annexin binding buffer 
diluted 1:10 in ddH2O (B. Braun Melsungen AG, Cat. No.: 0082479E). Subsequently, 
1.5µl Annexin V-FITC was added to each tube. After an incubation period of 10min at 
room temperature in the dark, cells were washed once with 1x binding buffer and 
pellets were cerefully resuspended in 150µl 1x binding buffer. 7µl of PI  was added 
immediately before flow cytometric analysis. The percentage of Annexin V single 
positive and Annexin V/PI double positive cells was then determined (total of early 
and late apoptotic cells). Sensitivity was defined as follows: <10% apoptosis 
compared to untreated cells: resistant; 10%-40%: moderately sensitive; >40%: highly 
sensitive.  
  
 
Figure 10: Measurement of apoptosis using Annexin V/PI staining. Early apoptotic cells are 
Annexin V positive but PI negative (lower right panel), Late apoptotic cells additionally stain positive 
for PI (upper right panel). Living cells are not stained by either reagent (lower left panel). Figure taken 
from Bordón et al., 2009200 
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3.7 Europium-TDA release assay 
The Europium-TDA release assay can be used to measure cell-mediated cytotoxicity. 
12, 201
 Target cells are labeled with a fluorescence enhancing ligand (BATDA) before 
incubation with the effector cells. Inside the cells, BATDA is hydrolysed, forming a 
compound (TDA) which can no longer penetrate the cellular membrane. During cell 
lysis, cytoplasmic TDA is released into the cell culture supernatant by labeled cells. 
When the supernatant is then introduced into the europium solution, TDA forms a 
highly fluorescent chelate with europium (EuTDA, Figure 11). This fluorescence can 
be detected by time-resolved fluorescence measurement and correlates directly with 
target cell lysis. 
 
 
 
Figure 11: Principle of the Europium-TDA release assay 
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3.7.1 Experimental procedure 
Europium solution: 
 Europium solution (Perkin Elmer, Cat. No.: C135-100) 
BATDA reagent: 
BATDA reagent (Perkin Elmer, Cat. No.: C136-100) 
Lysis buffer: 
Culture medium 
2% v/v Triton X (Neuber, Cat. No.: 12298.0100) 
 
Effector cells (pDCs) were isolated the day before the assay and were either 
stimulated with Roferon®-A  or IMQ over night, or left unstimulated. 
On the day of the assay, target cells were harvested and resuspended in standard 
medium to a final concentration of 106 cells/ml. Cells were then labeled for 30min in a 
37°C waterbath with 4µl/ml (Jurkat) or 2µl/ml (melanoma) BATDA reagent. After 
labeling cells were washed five times in antibiotic-free medium to remove excess 
labeling reagent.  
2-3x103 target cells were coincubated with pDCs in duplicates in a round-bottom 96-
well plate at an effector to target ratio (E:T) of 20:1. 100 ng/ml SuperKillerTRAIL™ 
served as a positive control for TRAIL-mediated killing. TRAIL-dependence of pDC-
mediated killing was assessed by pretreating the stimulated pDCs with a neutralizing 
antibody against TRAIL (R&D, Cat. No.: MAB375) for 30 min before the assay. A 
mouse IgG1 isotype served as negative control. For spontaneous and maximum 
release cells were treated with 100µl medium alone and lysis buffer, respectively. 
The inherent cytotoxicity of the labeling agent BATDA limited maximum incubation 
time in a cell type-dependent manner. After 2h (Jurkat), 4h (SkMel2) or 6h (WM793) 
incubation plates were centrifuged for 5min at 601xg and 20µl cell culture 
supernatant were transferred into a 96-well FluoroNunc™ plate (Nunc, Cat. No.: 
437869). 200µl Europium solution was added to each well containing supernatant 
and the plate was incubated for 15min on a shaker at room temperature in the dark. 
Fluorescence was determined using a Wallac 1234 Delfia® Fluorometer. Specific 
Lysis (L) was calculated in percent using the formula L=(E-S)/(M-S)x100 (E=counts 
in wells treated with effector cells or SuperKillerTRAIL™; S=spontaneuos Lysis in 
wells with medium only; M=maximum Lysis in wells treated with lysis buffer).   
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3.8 3H-Thymidine Proliferation assay 
3H-Thymidine solution 
0.5ml 3H-Thymidine (Perkin Elmer, Cat. No.: Net027005MC) 
9.5ml RPMI 1640 
 
All steps involving radioactivity were performed with the help of Dr. F. Koszik, 
radiation safety officer.  
 
Measurement of cell proliferation was performed in triplicates. Proliferation rates 
were assessed 24h, 48h and 96h after IFN-α-stimulation. For each of the three 
timepoints one flat-bottom 96-well plate was prepared. Melanoma cells were seeded 
at a density of 3000-10000 cells/well. The next day, 0-105 U/ml Roferon®-A  were 
added. 3.7x104Bq 3H-Thymidine were added to each well 0h, 24h, or 72h after IFN-α 
stimulation. After 24h of 3H-Thymidine incorporation plates were frozen at -20°C.  
3.8.1 Detection of radioactivity 
For the detection of radioactivity plates were thawed at 37°C and radioactively 
labeled DNA was transferred to a glass filtermat (Wallac, Cat. No.: 1205-401) using a 
Tomtec Mach II M Harvester. Together with a MeltiLex™ Melt-on Scintillation Sheet 
(Perkin Elmer, Cat. No.: 1205-441) the filtermat was then heat-sealed in a plastic bag 
and radioactivity was determined using a Wallac 1205 Betaplate Liquid Scintillation 
counter. 
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4 RESULTS 
4.1 Characterization of melanoma cell lines 
Before their use in this study, the established melanoma cell lines SkMel2, SkMel28 
and MeWo as well as the melanoma cell lines Pat1-4, generated from metastases of 
stage IV melanoma patients, were tested for contamination with mycoplasma. 
Subsequently the cells were examined for their expression of MHC class I and II, 
which is often aberrant in tumor cells as well as for TRAIL and TRAIL R expression.  
4.1.1 Melanoma cell lines are free of mycoplasma contamination 
As shown by the lack of small spots of extranuclear fluorescence, the cell lines used 
were free of mycoplasma contamination (Figure 12).  
 
 
 
 
 
Figure 12: Melanoma cell lines are free of mycoplasma. A) DAPI-stained nuclei of three selected 
cell lines. No extracellular fluorescence indicating contamination was detected after a minimum of two 
passages in antibiotic free medium. B) A mycoplasma-free sample (left) compared with a 
contaminated culture (right). Photos in B were taken from Nir-Paz et al., 2002.202  
Pat 1 SK Mel 2 Pat 3 
A 
B 
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4.1.2 Surface expression of MHC class I and II  
In this study, the expression of MHC class I (HLA-ABC) and MHC class II (HLA-DR) 
on the cell surface was assessed using flow cytometry. The results obtained show 
that all cell lines except for Pat2 cells expressed high levels of MHC class I on their 
surface. MHC II was found only on Pat1 cells (Figure 13, Table 10).  
MHC I MHC II
isotype
antibody
MeWo
 
Figure 13: Surface expression of MHC class I and II on MeWo cells. Figure shows a 
representative example of FACS analysis using MeWo cellls. 
 
Table 10: Surface expression of MHC class I and II on melanoma cell lines. Data obtained by flow 
cytometry in a minimum of three independent experiments. (++: strong expression (MFI>10); +: weak 
expression; -: no expression) 
 
-++Pat4
-++Pat3
--Pat2
++++Pat1
-++MeWo
-++SkMel28
-++SkMel2
MHC IIMHC ICell line
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4.1.3 Expression of TRAIL and TRAIL receptors 
The expression of TRAIL and its receptors was assessed at the protein and mRNA 
level. 
TRAIL and TRAIL R surface expression was assessed using flow cytometry. None of 
the melanoma cell lines tested expressed TRAIL on their surface. Of the DRs, TRAIL 
R2 was found on all cell lines, whereas TRAIL R1 was not detected. Minute levels of 
TRAIL R3 were found on SkMel28, Pat1, Pat2 and Pat3 cells. Only Pat3 cells 
showed TRAIL R4 expression, albeit at a very low level (Figure 14, Table 11).  
TRAIL TRAIL R3 TRAIL R4TRAIL R1 TRAIL R2
antibody
isotype
 
Figure 14: Surface expression of TRAIL and TRAIL R on MeWo cells. Figure shows a 
representative FACS analysis of TRAIL and TRAIL R expression on MeWo cells. 
 
Table 11: Surface expression of TRAIL and TRAIL R on established and patient-derived 
melanoma cell lines. Data obtained by flow cytometry in a minimum of three independent 
experiments. (++: strong expression (MFI>10); +: weak expression; -: no expression) 
--++--Pat4
+++--Pat3
-+++--Pat2
-+++--Pat1
--++--MeWo
-++--SkMel28
--+--SkMel2
TRAIL R4TRAIL R3TRAIL R2TRAIL R1TRAILCell line
 
 
Next, mRNA levels of TRAIL and TRAIL R were determined using real time PCR and 
the results were compared to the flow cytometry data. Figure 15 shows the relative 
mRNA levels of TRAIL and TRAIL R. The mRNA expression in Pat3 cells could not 
be compared to those of the other cell lines, due to a great difference in the levels of 
the reference gene GAPDH. This was also the case when another housekeeping 
gene (β-Actin) was used as reference (data not shown). 
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The results of flow cytometry were reflected in the mRNA data by the fact that TRAIL 
R2 mRNA levels were generally 2log higher than those of the other receptors or 
TRAIL itself.  
 
Figure 15: TRAIL R2 mRNA levels were generally 2-log higher compared to those of other 
TRAIL receptors. Levels of mRNA were determined by real time PCR and normalized to GAPDH 
expression. Data show mean RNA levels ± SD of two independent experiments performed in 
duplicates. 
 
 
Taken together, the results from flow cytometry and real time PCR show that due to 
their expression of TRAIL R2, all melanoma cell lines tested are potential targets for 
TRAIL-mediated cytotoxicity. 
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4.2 Apoptotic and antiproliferative effects of IFN-α on melanoma 
cells 
It has previously been been shown that IFN-α may influence tumor progression not 
only due to its immune-activating effects but also via direct effects on tumor cells 
(see 2.2.2).7, 8 We therefore assessed the effect of IFN-α on melanoma cell 
proliferation and apoptosis. 
4.2.1 Selection of IFN-α  
Two recombinant IFN-α compounds, Roferon®-A (IFN-α2a) and Intron®A (IFN-α2b), 
are available for adjuvant melanoma therapy in Austria. IFN-α2a and IFN-α2b are two 
allelic variants of the IFN-α2 gene. Although they only differ in two amino acid 
positions203, this distinction might affect the response of IFN-α receptor-bearing cells. 
Further, the composition of the drugs (e.g. salt, pH) might influence their activity. To 
ensure that the effects observed in this study are not attributable to unique properties 
of one IFN-α2 compound, Intron®A and Roferon®-A were compared in their ability to 
induce TRAIL on different PBMC subsets and their effect on melanoma cell 
proliferation and viability using SkMel2 cells.  
The expression of TRAIL on PBMCs was assessed after over night incubation of 
isolated PBMCs with Roferon®-A or Intron®A (50,000 IU/ml) and, in addition IMQ 
(5µg/ml). The expression of TRAIL on CD3+ (T cells), CD14+ (monocytes), and 
CD19+ (B cells) subsets was assessed the next day using flow cytometry.  
Both IFNs induced comparable levels of TRAIL on all subsets analyzed (Figure 16). 
Stimulation of TRAIL expression was strongest in CD14+ monocytes and weakest in 
CD3+ T cells. IMQ did not induce TRAIL in any of the subsets tested. As we have 
previously shown, IMQ-induced expression of TRAIL on pDCs depends on the 
induction of type I IFNs.14 The lack of TRAIL expression on B cells, T cells and 
monocytes upon IMQ-stimulation is probably due to insufficient induction of type I 
IFNs on these cell types. 204, 205  
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Figure 16: Roferon®-A and Intron®A induce comparable levels of TRAIL on monocytes, B cells 
and T cells whilst IMQ does not induce TRAIL. TRAIL expression was determined by flow 
cytometry after 24h stimulation with Roferon®-A Intron®A (50,000 IU/ml) or IMQ (5 µg/ml). Cells were 
gated on CD14 (monocytes), CD19 (B-cells) and CD3 (T-cells). Histograms show results of one 
experiment performed.  
 
To assess the effect of Roferon®-A and Intron®A on melanoma cell viability, SkMel2 
cells were treated with Roferon®-A or Intron®A for 24-96h. The percentage of viable 
cell was determined via Annexin V/PI staining.  
Both IFNs lead to a slight decrease in viablility of SkMel2 cells after 96h treatment 
with 1,000 IU/ml. The results obtained were nearly identical with both compounds 
(Figure 17 A). 
Proliferation of SkMel2 cells was assessed after 24-96h treatment with Roferon®-A or 
Intron®A via 24h 3H-Thymidine incorporation. Both IFN-α compounds caused a 
comparable, concentration-dependent decrease in proliferation (Figure 17 B).  
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Figure 17: Roferon®-A and Intron®A have similar effects on SkMel2 viability and proliferation. A) 
Viability of SkMel2 cells after 24, 48 and 96h treatment with Roferon®-A or Intron®A determined by 
Annexin V/PI staining (n=1). B) Proliferation of SkMel2 cells determined by 3H-Thymidine 
incorporation. Data shown represent mean 3H-Thymidine incorporation +/- SD of one experiment 
performed in triplicates. 
 
Since no differences were found between the effects of Intron®A and Roferon®-A in 
any of the above experiments, Roferon®-A was arbitrarily chosen to be used in this 
study. 
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4.2.2 IFN-α inhibits proliferation but does not induce apoptosis in melanoma 
cells  
We next assessed the apoptotic and antiproliferative effects of IFN-α on melanoma 
cells. 
Apoptosis induced by IFN-α was measured after 24-72h treatment with different 
doses of IFN-α using Annexin V/PI staining. In general the melanoma cells were 
resistant to IFN-α-induced apoptosis. Even when stimulated with 10,000 IU/ml and 
after 72h of treatment, apoptosis was not induced in most of the cell lines. Only Pat4 
cells showed low sensitivity (12%) to IFN-α after treatment with the maximum dose 
for 48h and above (Figure 18 A). 
 
 
Figure 18: Effect of IFN-α on melanoma cell apoptosis and proliferation. A) Apoptosis of 
melanoma cells upon treatment IFN-α for 24, 48 and 72h as determined by Annexin V/PI staining. 
Data shown represent mean apoptosis ± SD (n=2). B) Melanoma cell proliferation upon treatment with 
different concentrations of IFN-α for 24, 48 and 96h. Data show mean proliferation ± SD of two 
independent 24h 3H-Thymidine incorporation assays performed in triplicates.  
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Melanoma cell proliferation was measured via 24h 3H-Thymidine incorporation after 
24-96h of incubation with IFN-α (0-10,000 IU/ml). Consistent with previous findings,7, 
74
 IFN-α inhibited melanoma cell proliferation in a concentration-dependent fashion 
(Figure 18 B). This effect was most pronounced in Pat1 and Pat2 cells (max. 
Reduction of proliferation: about 60% after 96h treatment with 10,000 IU/ml 
Roferon®-A compared to untreated). The smallest reduction of proliferation compared 
to untreated cells was seen in MeWo cells (about 30%).  
 
Taken together these results show that IFN-α affects melanoma cell proliferation but 
does not induce apoptosis in the melanoma cell lines tested. 
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4.3 TRAIL-induced apoptosis in melanoma cells  
Next, we assessed the sensitivity of the melanoma cell lines to skTRAIL using 
Annexin V/PI staining. In three independent experiments, the sensitivity of the 
melanoma cells to TRAIL was determined after 16h incubation with skTRAIL (1-100 
ng/ml). Results obtained show that SkMel2 and SkMel28 cells were moderately 
sensitive to a 1 ng/ml dose of skTRAIL and highly sensitive when incubated with 10 
ng/ml or 100 ng/ml. MeWo, Pat1, Pat2 and Pat4 cells showed low sensitivity to 
skTRAIL only at the highest concentration. Pat3 cells were resistant to all 
concentrations of skTRAIL tested (Figure 19 A). 
 
Interestingly, the sensitivity of a given cell line to skTRAIL did not correlate with the 
level of surface expression of TRAIL R2, the DR detected on our cells, or its mRNA 
levels (Figure 19 B, C). Indeed, three of the cell lines with low susceptibility to TRAIL 
(MeWo, Pat2, Pat4) showed very high surface expression of TRAIL R2, whilst TRAIL 
R2 expression on the highly susceptible cell lines SkMel2 and SkMel28 was rather 
low.  
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Figure 19: TRAIL induces varying degrees of apoptosis in melanoma cells, irrespective of their 
TRAIL R expression.  Data in A show mean levels of apoptosis (± SD) induced by over night 
treatment with different concentrations of skTRAIL and normalized to untreated cells (n=3). B and C) 
Correllation of sTRAIL-induced apoptosis with mean fluorescence intensities of TRAIL R2 expression, 
determined by flow cytometry (B) and TRAIL R2 mRNA levels relative to GAPDH expression (C). (r 
indicates Pearson correlation coefficient). 
 
4.3.1 IFN-α but not IMQ enhances TRAIL-induced apoptosis in melanoma 
cells 
Effects of IFN-α on TRAIL-susceptibility: 
In a patient treated with IFN-α, melanoma cells may be simultaneously exposed to 
TRAIL induced by IFN-α and IFN-α itself. To examine whether IFN-α influences the 
extent of TRAIL-induced apoptosis, the susceptibility of melanoma cells to skTRAIL 
(100 ng/ml) was re-assessed after pretreatment with IFN-α. Whilst IFN-α alone did 
not induce apoptosis in melanoma cells, as previously shown (see 4.2), it significantly 
enhanced TRAIL-induced apoptosis in five out of seven cell lines tested (Figure 20). 
The effect was most pronounced in Pat4 cells which were only moderately sensitive 
to TRAIL alone (17% apoptosis), but highly sensitive when pretreated with IFN-α 
(48% apoptosis). These data demonstrate that IFN-α has a synergistic effect on 
TRAIL-induced apoptosis in melanoma. 
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Figure 20: IFN-α-pretreatment of melanoma cells enhances TRAIL-induced apoptosis. 
Representative dot plots (A) and quantitative analysis (B) of apoptosis induced by skTRAIL (100 
ng/ml) with or without 24h IFN-α pretreatment (1,000 IU/ml). Data in B show mean levels of apoptosis 
± SD normalized to untreated cells (n=3-5). (∗Significant difference between TRAIL-induced apoptosis 
after IFN-α-pretreatment compared to the sum of apoptosis induced by TRAIL and IFN-α alone 
(paired, two-tailed t-test; p<0.05). 
 
IFNs have been shown to modulate the expression of TRAIL Rs in vitro.206, 207 Table 
12, however, shows that in our study TRAIL-R and also TRAIL-expression on 
melanoma cells generally remained unchanged upon IFN-α treatment. The 
upregulation of MHC class I upon IFN-α treatment served as a positive control.78, 79 
Our data indicate that the enhancing effect of IFN-α on TRAIL-mediated apoptosis 
involves intracellular pro- or antiapoptotic molecules downstream of the TRAIL-TRAIL 
R interaction. 
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Table 12: Surface levels of TRAIL and TRAIL R are generally not altered by IFN-α. ++: strong 
expression; +: weak expression; -: no expression; (↓): downregulation; (↑): upregulation upon 24h 
treatment with IFN-α (1,000 IU/ml) as determined by flow cytometry (n=3). 
Cell line TRAIL TRAIL R1 TRAIL R2 TRAIL R3 TRAIL R4 MHC I 
SkMel2 - - + - - ++ (↑) 
SkMel28 - - + + - ++ (↑) 
MeWo - - ++ - - ++ (↑) 
Pat1 - - ++ + - ++ (↑) 
Pat2 - - ++ + - 
- 
Pat3 - - + + + (↓) ++ (↑) 
Pat4 - - ++ - 
- ++ (↑) 
 
 
Effect of IMQ on TRAIL susceptibility 
It has been shown that viral infections can increase cell susceptibility to TRAIL.208-210 
Since RNA viruses are natural ligands for TLR7/8, we asked whether the artificial 
TLR7/8 ligand IMQ might have a similar effect. We therefore assessed the effect of 
melanoma cell pretreatment with IMQ and/or IFN-α on TRAIL-induced apoptosis. 
However, our data indicate that IMQ does not affect melanoma cell sensitivity to 
TRAIL (Figure 21).  
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Figure 21: IMQ does not enhance TRAIL-induced apoptosis in melanoma cells. Data show 
apoptosis induced by skTRAIL (100 ng/ml), IFN-α (1,000 IU/ml) and/or IMQ (5 µg/ml) as determined 
by Annexin V/PI staining in one experiment per cell line. 
RESULTS - Induction of TRAIL on pDCs by IMQ and IFN-α 
 63 
4.4 Induction of TRAIL on pDCs by IMQ and IFN-α  
Type I IFNs have previously been shown to induce expression of TRAIL on pDCs.14, 
164
 The synthetic TLR7/8 ligand IMQ is another strong inducer of TRAIL on this cell 
type.12, 14, 164 To compare the effectivity of TRAIL-induction by both stimuli, human 
pDCs isolated from buffy coats were treated over night with different concentrations 
of IFN-α or IMQ and TRAIL expression was assessed the next day using flow 
cytometry. Our results show that both compounds induce TRAIL expression on 
pDCs. Interestingly, the maturation marker CD83 was upregulated upon IMQ 
stimulation, but not when pDCs had been stimulated with IFN-α  (Figure 22).  
 
 
Figure 22: Induction of TRAIL and CD83 on pDCs by IFN-α and IMQ. Expression of TRAIL and 
CD83 on pDCs freshly isolated from buffy coats, stimulated with IFN-α (10,000 IU/ml) or IMQ (5 µg/ml) 
over night was assessed by FACS analysis. Cells were gated on HLA-DR and BDCA-2 and purity was 
greater than 95%. Histograms shown are representative of five independent experiments. 
 
We and others have previously shown that IMQ-induced expression of TRAIL on 
pDCs is dependent on IMQ-induced expression of IFN-α.14, 164, 211 However, our 
results demonstrate that IMQ is a stronger inducer of TRAIL expression than IFN-α 
(Figure 22).  This indicates that TLR7/8 activation could provide a costimulatory 
signal for TRAIL expression. 
To test this hypothesis, isolated pDCs were incubated over night with increasing 
concentrations of IMQ in presence or absence of IFN-α (10,000 IU/ml). At a 
concentration of 0.05 µg/ml, IMQ did not induce TRAIL when used alone. In 
combination with IFN-α, however, low-dose IMQ enhanced TRAIL as well as CD83 
CD83 
TRAIL 
unstimulated                      IFN-α                          IMQ  
TRAIL 
isotype 
CD83 
isotype 
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expression, resulting in levels comparable to those seen when using high-dose IMQ 
(Figure 23).  
 
0                                   0.005                       0.05                                 0.5                  5                  µg/ml IMQ
TRAILA
0                                   0.005                       0.05                                 0.5                  5                  µg/ml IMQ
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w/o IFN-α
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w/o IFN-α
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Figure 23: IFN-α-induced expression of (A) TRAIL and (B) CD83 on pDCs is enhanced by IMQ. 
FACS staining after over night incubation of pDCs isolated from buffy coats with different 
concentrations of IMQ (as indicated under the histograms) with (red line) or without (black line) 10,000 
IU/ml IFN-α. (n=1) 
 
Next, the effect of low-dose IMQ (0.05 µg/ml) on TRAIL-induction with different 
concentrations of IFN-α was assessed. Low-dose IMQ without IFN-α did not 
stimulate TRAIL expression (Figure 24A). IFN-α alone induced expression of low 
levels of TRAIL already at concentrations as low as 50 IU/ml. In presence of low-
dose IMQ, TRAIL levels were markedly increased. The expression of the activation 
marker CD83 was also enhanced by low-dose IMQ (Figure 24B). 
Our findings demonstrate that TLR7/8 engagement has a costimulatory effect on 
induction of TRAIL on pDCs by IFN-α. 
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Figure 24: Low-dose IMQ enhances IFN-α-induced expression of TRAIL (A) and CD83 (B) on 
pDCs. Human pDCs isolated from buffy coats were assessed using flow cytometry after over night 
incubation with different concentrations of IFN-α (as indicated under the histograms) with (red line) or 
without (black line) 0.05 µg/ml IMQ. Histograms shown are representative of three independent 
experiments. This data is also shown in Kalb et al., 2012.14 
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4.5 Analysis of tumoricidal properties of pDCs 
4.5.1 TRAIL+ pDCs are capable of lysing TRAIL-sensitive cells 
To verify that TRAIL+ pDCs have cytotoxic potential, a conventional 2h EuTDA 
release cytotoxicity assay was performed using the highly TRAIL-susceptible Jurkat 
cell line as targets. Expression of TRAIL was confirmed on the day of assay using 
flow cytometry (Figure 25A).  
As expexted, unstimulated pDCs that do not express TRAIL did not exert cytotoxic 
effects. Both, IMQ- and IFN-α-stimulated pDCs effectively lysed Jurkat cells. 
Consistent with the higher induction of TRAIL, lysis was greatest when pDCs had 
been stimulated with IMQ rather than IFN-α (Figure 25B). These results show that 
IMQ- as well as IFN-α-stimulated pDCs are capable of lysing TRAIL-sensitive cells. 
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Figure 25: PDCs acquire TRAIL expression and are able to lyse Jurkat cells upon over night 
stimulation with IFN-α or IMQ. A) Induction of TRAIL on pDCs by IFN-α (50,000 IU/ml) and IMQ (5 
µg/ml) as determined by flow cytometry. Data in B represent mean lysis of one 2h EuTDA release 
assay performed in duplicates (E:T=20:1).  
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4.5.2 IFN-α- and IMQ- stimulated pDCs effectively lyse melanoma cells 
Topical IMQ and systemic IFN-α have been shown to be clinically effective in 
melanoma patients.2-5 In man and mice,  IMQ-induced regression of skin tumors was 
associated with an influx of pDCs that expressed TRAIL.12, 13, 133 To test whether 
TRAIL+ pDCs could have a role in IFN-α- and IMQ-mediated anti-melanoma activity, 
we studied the ability of human pDCs to lyse melanoma cells. SkMel2 and WM793 
cells, both highly TRAIL susceptible melanoma cell lines due to their expression of 
TRAIL R2 (Figure 26), were used as target cells. SkTRAIL served as a positive 
control.  
 
TRAIL R1 TRAIL R2
WM793
TRAIL R1 TRAIL R2
SkMel2
TRAIL R1/2
isotype
 
Figure 26: WM793 and SkMel2 cells express the proapoptotic receptor TRAIL R2 but no TRAIL 
R1. Histograms show flow cytometry results representative of a minimum of three independent 
experiments. 
 
Figure 27 clearly demonstrates that both IFN-α and IMQ- activated pDCs effectively 
lyse melanoma targets. There was no significant difference in melanoma cell lysis 
induced by IFN-α or IMQ-activated pDCs (T-test: p=0.43 and p=0.23 for SkMel2 and 
WM793, repectively). In all experiments lysis was reduced to baseline level when 
stimulated pDCs were pretreated with a neutralizing anti-TRAIL antibody, 
demonstrating the TRAIL-dependence of the cytotoxic effect.  
Taken together, these results show that IMQ- as well as IFN-α-stimulated pDCs are 
capable of killing susceptible melanoma cells in a TRAIL-dependent fashion. 
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Figure 27: IMQ- and IFN-α-stimulated pDCs lyse TRAIL-susceptible melanoma cells in a TRAIL-
dependent fashion.  Figure shows results of EuTDA release assays with SkMel2 cells (A) and 
WM793 cells (B) as targets. PDCs stimulated with IMQ (5 µg/ml) or IFN-α (25,000 IU/ml) were used as 
effector cells. Baseline levels of cytotoxicity were determined using unstimulated pDCs. TRAIL-
dependence of lysis was demonstrated using a neutralizing antibody against TRAIL (anti-TRAIL). 
SkTRAIL served as positive control for TRAIL-mediated lysis of melanoma cells. (n=3) 
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5 DISCUSSION 
Patients with high-risk primary melanoma may benefit from treatment with IFN-α in 
an adjuvant setting.2, 5 At the same time, there exist data that the topical treatment of 
cutaneous melanoma metastases with the TLR7/8 agonist Imiquimod, an IFN-α-
inducer on pDCs, may lead to the disappearance of the tumor.4 Many effects, 
including stimulation of the immune system and direct induction of apoptosis have 
been suggested to contribute to the positive effects observerd with these therapies.6-
10, 122
 In this diploma thesis, we sought to gain better insight in the mechanisms 
behind the anti-melanoma activity of IFN-α and IMQ with particular interest on the 
role of the cytotoxic molecule TRAIL. 
 
The initial characterization of the melanoma cell lines used in this study by flow 
cytometry showed that, among the different TRAIL R, only TRAIL R2 was expressed 
abundantly on all melanoma cell lines. Some cell lines also stained positive for 
TRAIL R3 (SkMel2, Pat1, Pat2, Pat3). TRAIL R4 was only detected on Pat3 cells, 
whereas all cell lines lacked TRAIL R1 and TRAIL (Figure 14). These results were 
reflected in our real-time PCR data as the mRNA levels of TRAIL R2 were generally 
2log higher than those of TRAIL or the other receptors (Figure 15). The presence of 
the DR TRAIL R2 on the cell surface indicates that all melanoma cell lines used in 
this study are potential targets for TRAIL-mediated cytotoxicity. Since only minute 
amounts of TRAIL R3 and TRAIL R4 were found on the melanoma cells, they are 
unlikely to interfere with TRAIL sensitivity by acting as decoy for TRAIL binding.145 In 
accordance with our results, Ren et al. showed that the majority of uveal melanoma 
cell lines express high levels of TRAIL R2, whereas expression of the other 
receptors for TRAIL generally was rather low.212 Another study, however, 
demonstrates that many melanoma cell lines express all four TRAIL receptors 
whereas some express none at all.146 
Previous studies have shown that about 66% of human melanoma cell lines are 
susceptible to TRAIL.213 In the present study, the melanoma cell lines used 
displayed different levels of TRAIL-sensitivity (Figure 19). Those derived from 
melanoma patients were generally less susceptible than the established cell lines 
from ATCC (6%-17% vs. 12%-54% apoptosis). This finding was not entirely 
unexpected, as the patient cell lines were derived from metastases of late stage 
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melanoma patients that had undergone previous treatments. The fact that these 
patients developed metastases indicates that these melanomas have developed 
resistance against therapy-induced anti-melanoma mechanisms. As TRAIL is 
suggested to be involved in tumor immunity, the patient cells may have encountered 
TRAIL and may have been selected for TRAIL resistance within the body prior to 
their isolation. Consistent with this hypothesis, Nguyen et al. have shown that TRAIL-
sensitive melanoma cell lines rapidly acquire resistance by downregulating TRAIL R 
expression when cultured in the presence of TRAIL.214  
It has been proposed that, in melanoma, TRAIL-sensitivity is largely dependent on 
the expression of TRAIL R2.146, 215, 216 This finding is partially reflected in our results 
by the fact that all melanoma cells expressed TRAIL R2 but not TRAIL R1. It is 
therefore plausible that the apoptotic signal is transduced via this receptor. However, 
in our system, TRAIL sensitivity did not correlate with TRAIL R2 protein or mRNA 
expression (Pearson correlation coefficient r=-0.47 and r=0.05, respectively; Figure 
19). This demonstrates that other factors also decide upon the faith of a cell after 
TRAIL-TRAIL R2 interaction. A multitude of pro- and antiapoptotic factors such as 
Bcl-2 have been shown to affect TRAIL signaling.155-157 Such proteins are likely to be 
key regulators of TRAIL-sensitivity and their expression in melanoma should be the 
subject of further investigation. 
Next, we assessed the antiproliferative and proapoptotic effects of IFN-α on 
melanoma cells. We found that IFN-α inhibits melanoma cell proliferation but does 
not induce apoptosis in melanoma cells (Figure 18). In 1997, Sangfelt et al. showed 
that growth arrest and induction of apoptosis are independent reactions to 
stimulation with IFN-α.7 Inhibition of cell growth by IFN-α appears to be associated 
with prolonged activation of STAT1 whereas an intact PI3K/mTOR pathway seems 
to be necessary for the induction of apoptosis.74, 89, 217 The activation of this pathway 
upon IFN-α-stimulation in melanoma cells may be of interest in future studies. 
Since IFN-α has previously been shown to enhance the sensitivity of malignant cells 
to apoptosis-inducing agents,76, 218 we also assessed the effect of melanoma cell 
pretreatment with IFN-α on TRAIL-induced apoptosis. Although no direct 
proapoptotic effect of IFN-α on melanoma cells was detected, IFN-α-pretreatment 
was found to enhance melanoma cell sensitivity to TRAIL (Figure 20). The increase 
in apoptotic cell death was significant in five out of seven cell lines and most 
pronounced in Pat4 cells (from 17% to 48%). Even the TRAIL-resistant melanoma 
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cell line Pat3 became moderately sensitive upon IFN-α pretreatment. This interesting 
finding suggests effects of IFN-α on the expression of TRAIL R or other molecules of 
the apoptotic cascade. It has been previously proposed that IFN-α can affect the 
TRAIL-susceptibility of Daudi B lymphoma cells and human hepatoma cells through 
alteration of TRAIL R surface expression.206, 219 However, we detected no effect of 
IFN-α on TRAIL or TRAIL R expression on melanoma cells (Table 12). This indicates 
that IFN-α acts on apoptotic factors downstream of the TRAIL-TRAIL R interaction. 
Microarray studies have shown that type I IFN affect the expression of a variety of 
genes involved in apoptosis, including X-linked inhibitor of apoptosis-associated 
factor-1 (XAF1).70 This protein appears to be one regulator of TRAIL sensitivity in 
melanoma as overexpression of this protein potently sensitized A375 melanoma 
cells to TRAIL.220 The proteins responsible for enhanced TRAIL-sensitivity upon IFN-
α treatment might have potential as therapeutic targets themselves and should 
therefore be subjected to further examination. 
 
Another factor that is known to increase cellular sensitivity to TRAIL is viral 
infection.210, 221, 222 We therefore asked whether, by mimicking a viral infection in 
melanoma cells, IMQ could also enhance TRAIL-mediated cytotoxicity. Direct effects 
of IMQ on melanoma cells have already been proposed. Schön et al. have shown 
that high doses of IMQ can induce apoptosis in melanoma cells.127 However, they 
demonstrate that this phenomenon is independent of the activation of TLR7/8 and 
rather functions via interaction with the adenosine receptor pathway. Cellular 
systems for the detection of viral infection are highly sensitive and capable of 
detecting minute amounts of virus components. We therefore chose a lower 
concentration of IMQ that would not induce apoptosis by itself to study the effects of 
IMQ on TRAIL-induced apoptosis. In our system, IMQ did not sensitize melanoma 
cells to TRAIL. Consistent with this finding, Goto et al. found that melanoma cell lines 
express little or no mRNA for TLR7 and TLR8.223 Our findings indicate that, although 
high concentrations may directly induce apoptotic cell death in melanoma cells, IMQ 
has no enhancing effect on TRAIL-induced apoptosis. However, topical treatment 
with IMQ is known to cause an infiltration of pDCs.11, 12 These cells produce large 
amounts of IFN-α when stimulated with IMQ.224 PDC-derived IFN-α could therefore 
sensitize melanoma cells to TRAIL in IMQ-treated patients. 
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Taken together, our data on TRAIL-induced apoptosis in melanoma cells indicate 
that TRAIL could have a role in anti-melanoma immunity but melanoma cells often 
acquire resistance to TRAIL in affected patients. During topical IMQ treatment and 
IFN-α therapy, however, TRAIL sensitivity of melanoma cells may be restored. 
 
To conclude the study, we looked into one potential aspect of IFN-α- and IMQ-
induced anti-melanoma immunity, i. e. the generation of cytotoxic pDCs.12, 13 The 
finding that DCs can acquire cytotoxic molecules upon proper stimulation challenges 
the classical view of DCs being antigen-presenting cells only.119 Interestingly, the 
expression of these molecules in DCs is subtype-dependent. Stimulation with IMQ 
leads to the expression of granzyme B and perforin in mDCs whereas pDCs are 
induced to express TRAIL on their surface.14  
PDCs appear to be particularly important in the treatment of cutaneous malignancies 
with topical IMQ.11, 12, 133 Recently, it has been shown in a murine melanoma model 
that topical treatment with IMQ leads to tumor clearence via the conversion of pDCs 
into TRAIL+ and Granzyme B+ cytotoxic effector cells.13 Our group has further 
demonstrated that the induction of TRAIL on pDCs by IMQ is dependent on IFN-α 
and that IFN-α itself can stimulate pDCs to express TRAIL in vitro.14 We therefore 
asked whether cytotoxic TRAIL+ pDCs could play a role in IMQ- and IFN-α-mediated 
tumor containment in melanoma patients. To this end, we first assessed the 
expression of TRAIL on human peripheral blood pDCs after overnight stimulation 
with IMQ/IFN-α using flow cytometry. Both compounds induced the expression of 
TRAIL on pDCs (Figure 22). IMQ strongly induced the expression of the maturation 
marker CD83 on pDCs whereas little or no upregulation of CD83 was detected upon 
IFN-α stimulation (Figure 22), indicating that pDC maturation was not required for the 
induction of TRAIL.  
Interestingly, TRAIL expression on pDCs was considerably higher upon IMQ 
stimulation than after incubation with IFN-α (Figure 22). Since we have previously 
shown that IMQ-mediated induction of TRAIL is dependent on IFN-α,14 this result 
sugests that TLR7 engagement can provide an enhancing stimulus for IFN-α-
induced TRAIL expression. Indeed, when pDCs were incubated with IFN-α and a 
dose of IMQ that was too low to induce TRAIL on pDCs by itself, TRAIL expression 
was increased significantly and could also be induced using lower concentrations of 
IFN-α (Figure 23 and Figure 24). This finding indicates that combination of adjuvant 
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IFN-α therapy with subclinical doses of IMQ might potentiate TRAIL-mediated 
cytotoxicity of pDCs in melanoma patients. Combination therapy with IFN-α and IMQ 
also might reduce the dosage of IFN-α required for the induction of TRAIL on pDCs 
thus lowering systemic side effects.  
 
Our results confirm that both, IFN-α and IMQ, are potent inducers of TRAIL on 
human peripheral blood pDCs. Together with the finding that i) a portion of 
melanoma cell lines is sensible to TRAIL and ii) pDCs are found in the inflammatory 
infiltrate of IMQ-treated skin tumors,11 this supports the notion that TRAIL+ pDCs 
may acquire cytotoxic effector functions and promote tumor clearence in IFN-α- and 
IMQ-treated melanoma patients. It has previously been shown that the human pDC 
model cell line GEN2.2 lyses melanoma cells in a TRAIL-dependent fashion.164 In 
the present study, the cytotoxic potential of freshly isolated pDCs from human blood 
was assessed using the EuTDA release assay. Our data clearly demonstrate that 
freshly isolated pDCs from human blood stimulated with IFN-α or IMQ lyse TRAIL-
sensitive melanoma cells in vitro (Figure 27). The cytotoxicity of pDCs was 
dependent on TRAIL, as lysis was reduced to baseline levels in presence of a 
neutralizing anti-TRAIL antibody. This finding suggests that cytotoxic pDCs play a 
role in the anti-melanoma effects of adjuvant IFN-α and topical treatment with IMQ. 
Further studies on murine melanoma models and on tumor samples from patients  
treated with IMQ or IFN-α will be needed to evaluate the in vivo relevance of this 
mechanism. 
 
Taken together, our data indicate that the induction of TRAIL on immune cells could 
play a role in IFN-α- and IMQ-mediated melanoma containment. Particularly pDCs 
may acquire important TRAIL-dependent cytotoxic effector functions in both 
therapeutic settings.  
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7 APPENDIX 
7.1 List of abbreviations 
AJCC American Joint Committee on Cancer 
ATCC American Type Culture Collection 
BCC  basal cell carcinoma 
BDCA blood dendritic cell antigen 
BSA bovine serum ablumin 
DC dendritic cell 
     mDC myeloid dendritic cell 
     pDC plasmacytoid dendritic cell 
DD death domain 
     FADD Fas-associated DD 
DEPC diethylpyrocarbonate 
DISC death-inducing signaling complex 
DITC dacabazine 
DMSO dimethyl sulfoxide 
DR  death receptor 
dsRNA double-stranded RNA 
E:T effector to target ratio 
Eu Europium 
FACS fluorescence-activated cell sorting 
FCS fetal calf serum 
GAS interferon-γ-activated sites 
IFN  interferon 
IFN-α  interferon-α  
IFNAR IFN-α receptor 
IL-2 interleukin-2 
IMQ  imiquimod 
IRFs interferon regulatory factors 
ISG interferon-stimulated gene 
ISGF3 interferon-stimulated gene factor 3 
JAKs janus kinase 
lin- lineage negative 
LN lymph node 
MACS magnetic-activated cell sorting 
MAPK mitogen-activated protein kinase 
MFI mean-fluorescence intensity 
MHC major histocompatibility complex 
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NK cells natural killer cells 
PBMCs peripheral blood mononuclear cells 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PI  propidium iodide 
SCC squamous cell carcinoma 
SD  standard deviation 
ssRNA single-stranded RNA 
STATS signal transducers and activators od transcription 
TLRs toll-like receptors 
TNF tumor necrosis factos 
TNM classification tumor-node-metastasis classification 
TRAIL TNF-related apoptosis-inducing ligand 
   memTRAIL membrane-bound TRAIL 
   rhTRAIL recombinant human TRAIL 
   skTRAIL SuperKillerTRAIL™ 
   sTRAIL soluble TRAIL 
TRAIL R1-4 TRAIL receptor 1-4 
Tregs regulatory T cells 
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7.4 Abstract 
Patients with high-risk primary melanoma may benefit from treatment with Interferon- 
α (IFN-α) in an adjuvant setting. At the same time, there exist data that the topical 
treatment of cutaneous melanoma metastases with the TLR7/8 agonist Imiquimod 
(IMQ), an IFN-α-inducer on plasmacytoid dendritic cells (pDCs), may lead to the 
disappearance of the tumor. Direct anti-tumor activity as well as stimulation of the 
immune system are thought to contribute to the efficacy of both agents. The 
induction of the cytotoxic molecule tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL), particularly on pDCs, might play an important role in IFN-α- and IMQ-
mediated melanoma containment. Both in man and mice, the regression of 
cutaneous tumors upon topical IMQ-treatment was associated with an infiltrate of 
pDCs expressing TRAIL. Since IMQ-induced TRAIL expression was shown to be 
dependent on IFN-α in vitro, TRAIL+ pDCs could also play a role in melanoma 
patients treated with IFN-α.  
In this diploma thesis, we focus on the role of TRAIL in the treatment of melanoma 
with IFN-α or IMQ. We were particularly interested in: i) direct apoptotic and 
antiproliferative effects of IFN-α on melanoma cells ii) susceptibility of different 
melanoma cell lines to TRAIL, iii) the correlation of TRAIL-sensitivity with TRAIL 
receptor (TRAIL R) expression and iv) whether IMQ- and IFN-α-activated pDCs 
acquire TRAIL-dependent cytotoxic effector functions against melanoma cells in 
vitro. 
To this end, we first characterized established melanoma cell lines and such 
generated from stage IV melanoma patient metastases with respect to their TRAIL 
and TRAIL receptor expression using flow cytometry and real-time PCR. We found 
that the death receptor TRAIL R2 was expressed abundantly on all melanoma cell 
lines, making them potential targets for TRAIL-mediated cytotoxic effects. We next 
assessed the susceptibility of melanoma cell lines to TRAIL by flow cytometric 
Annexin V/PI staining. Our results show that overnight treatment with soluble TRAIL 
induced different levels of apoptosis in the melanoma cell lines. Apoptosis was 
further increased by pretreatment of the melanoma cells with IFN-α. Finally, we 
assessed the cytotoxic potential of IFN-α or IMQ-activated pDCs against melanoma 
targets. Using Europium-TDA release cytotoxicity assays, we show that both, IMQ- 
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and IFN-α-activated pDCs effectively lyse melanoma cells in a TRAIL-dependent 
fashion.  
Our data indicate that the induction of TRAIL on immune cells could play a role in 
IFN-α- and IMQ-mediated melanoma containment. Particularly pDCs might acquire 
important TRAIL-dependent cytotoxic effector functions in both therapeutic settings. 
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7.5 Zusammenfassung 
Adjuvantes Interferon-α (IFN-α) kann in Hochrisiko-Melanompatienten das 
rezidivfreie Überleben und das Gesamtüberleben in geringem Maße verlängern. 
Weiters gibt es Hinweise darauf, dass topische Applikation des TLR7/8 Agonisten 
Imiquimod (IMQ) - einem Aktivator von IFN-α-Expression in plasmazytoiden 
dendritischen Zellen (pDZ) - zur Regression von kutanen Melanommetastasen 
führen kann.  
Sowohl direkte Effekte gegen Tumorzellen, als auch eine Aktivierung des 
Immunsystems dürften zur Wirkung beider Substanzen beitragen. Die Induktion des 
zytotoxischen Moleküls Tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL), insbesondere auf pDZ, könnte hierbei eine wichtige Rolle spielen. Sowohl 
bei Menschen als auch bei Mäusen war die Regression von Hauttumoren nach 
topischer IMQ-Behandlung mit einem Infiltrat TRAIL-exprimierender pDZ assoziiert. 
Da nachgewiesen wurde, dass die Induktion der TRAIL-Expression durch IMQ in 
vitro von IFN-α abhängig ist, könnten TRAIL+ pDZ auch in der Therapie von 
Melanompatienten mit IFN-α eine Rolle spielen. 
 
Diese Diplomarbeit beschäftigt sich mit der Bedeutung von TRAIL in der Behandlung 
von Melanomen mit IFN-α oder IMQ. Besonderes Interesse gilt dabei i) direkten 
apoptotischen und antiproliferativen Effekten von IFN-α auf Melanomzellen, ii) der 
Empfindlichkeit verschiedener Melanomzelllinien gegen TRAIL, iii) der Korrelation 
der TRAIL-Sensitivität mit der TRAIL-Rezeptorexpression und iv) der Frage, ob in 
vitro mit IMQ und IFN-α aktivierte pDZ TRAIL-abhängige zytotoxische 
Effektorfunktionen erwerben. 
 
Hierfür wurden zunächst etablierte und aus Metastasen von Melanompatienten im 
vierten Tumorstadium generierte Melanomzelllinien bezüglich TRAIL- und TRAIL-
Rezeptorexpression mittels Durchflusszytometrie und real-time PCR charakterisiert. 
Es zeigte sich, dass der Death Receptor TRAIL R2 auf allen Melanomzelllinien 
exprimiert ist, was diese Zellen als potentielle Ziele für TRAIL-vermittelte 
zytotoxische Effekte ausweist. Anschließend wurde die Empfindlichkeit der 
Melanomzelllinien gegenüber TRAIL mit Hilfe von durchflusszytometrischer Annexin 
V/PI Färbung untersucht. Die erworbenen Ergebnisse zeigen, dass die Behandlung 
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von Melanomzellen mit löslichem TRAIL über Nacht Apoptose in unterschiedlichem 
Ausmaß induziert, welches insbesondere durch Vorbehandlung der Zellen mit IFN-α 
erhöht wird. Letztendlich wurde das zytotoxische Potential von mit IFN-α oder IMQ 
stimulierten pDZ gegen Melanomzellen evaluiert. Mit Europium-TDA release 
cytotoxicity assays wurde gezeigt, dass sowohl IMQ-, als auch IFN-α-aktivierte pDZ 
Melanomzellen effektiv und TRAIL-abhängig lysieren können.  
 
Die Daten dieser Arbeit zeigen, dass die Induktion von TRAIL auf Immunzellen eine 
wesentliche Bedeutung bei der Kontrolle von Melanomen durch IFN-α und IMQ 
haben könnte. Insbesondere pDZ könnten hierbei wichtige TRAIL-abhängige 
zytotoxische Effektorfunktionen erwerben.  
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